 
 
 
Cli nic al St u d y Pr ot oc ol  
 
 
A Ra n d o mize d, D ose -ra n ge Fi n di n g St u d y t o E val uate P har mac o ki netics of 
Me dr o x y pr o gester o ne Acetate F oll o wi n g a Si n gle  S u bc uta ne o us A d mi nistrati o n of  
T V -[ADDRESS_1083810] u d y N u m ber T V 4 6 0 4 6 -W H -1 0 1 5 9  
 
 
N C T 0 4 6 8 2 3 5 3  
 
 
Pr ot oc ol wit h A me n d me nt 0 2  A p pr o val Date: [ADDRESS_1083811] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083812] er o ne Acet ate F oll o wi n g a Si n gle S u bc ut a ne o us A d mi nistr ati o n of  
T V -4 6 0 4 6 i n He alt h y W o me n of Re pr o d ucti ve A ge  
P h ase 1  
I N D n u m ber: [ADDRESS_1083813] a C T n u m ber: N ot a p plic a ble  
Cl i nic al St u d y Pr ot oc ol wit h A me n d me nt 0 2 Versi o n D ate: 1 6  M a rc h  2 0 2 1   
 
S p o ns or  M o nit or  
Te va Bra n d e d P har mace utical  
Pr o d ucts R & D, I nc.  
[ADDRESS_1083814] C hester, Pe n ns yl va nia  1 9 3 8 0  
U nite d States  F HI 3 6 0  
 
 
A ut h orize d Re pres e nt ati ve  
 
 
Te va Bra n d e d P har mace utical  
Pr o d ucts R & D, I nc.  
[ADDRESS_1083815] C hester, Pe n ns yl va nia  1 9 3 8 0  
U nite d States  
S p o ns or’s Me dic al E x pert  S p o ns or’s S afet y Re prese nt ati ve  
 
 
N u ve ntra, I n c. ™  
 
 
 
  
  
Gl o bal Patie nt  Safet y & 
P har mac o vi gila nce  
Te va Bra n d e d P har mace utical  
Pr o d ucts R & D, I nc.  
Tel:  
T his cli nical st u d y will be c o n d ucte d i n acc or da nce wit h c urre nt G o o d Cli nical Practice ( G C P) as directe d 
b y t he pr o visi o ns of t he I nter nati o nal C o u ncil f or Har m o nisati o n (I C H); U nite d States ( U S) C o de of 
Fe deral Re g ulati o ns ( C F R), a n d E ur o pea n U ni o n ( E U) Directi ves a n d Re g ulati o ns (as a p plica ble i n t he 
re gi o n of t he st u d y); nati o nal c o u ntr y le gislati o n; a n d t he s p o ns or’s Sta n dar d O perati n g Pr oce d ures 
( S O Ps).  
V V- [ADDRESS_1083816] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083817] ate me nt  
T his d oc u me nt c o ntai ns c o nfi de ntial a n d pr o prietar y i nf or mati o n (i ncl u di n g c o nfi de ntial c o m mercial 
i nf or mati o n p urs ua nt t o 2 1 C F R § 2 0. 6 1) a n d is a c o nfi de ntial c o m m u nicati o n of © 2 0 2 1 T e va Bra n de d 
P har mace utical Pr o d ucts R & D, I nc a n d/ or its affiliates. T he reci pie nt a grees t hat n o i nf or mati o n 
c o ntai ne d herei n ma y be p u blis he d or discl ose d wit h o ut writte n a p pr o val fr o m t he s p o ns or.  
© 2 0 2 1 T e va Bra n de d P har mace utical Pr o d ucts R & D, I nc. Al l ri g hts reser ve d.  
V V- [ADDRESS_1083818] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083819] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 3 D O C U M E N T HI S T O R Y  
 
A me n d me nt 0 2  1 6  Marc h  2 0 2 1  
1 0 s u bj ects e nr olle d t o date  
A me n d me nt  0 1  0 2 J ul y 2 0 2 0  
0 s u bj ects e nr olle d t o date.  
Ori gi nal Pr ot oc ol  0 4 Marc h 2 0 2 0  
T he S u m mar y of C ha n ges t o t he Pr ot oc ol i ncl u des t he c orres p o n di n g reas o n/j ustificati o n f or 
eac h c ha n ge a n d is pr o vi de d i n Secti o n [ADDRESS_1083820] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083821] o x y pr o gester o ne A cetate F oll o wi n g a Si n gle S u bc uta ne o us A d mi nistrati o n of T V -4 6 0 4 6 i n 
Healt h y W o me n of Re pr o d ucti ve A ge  
 
Versi o n Date: [ADDRESS_1083822] u d y.  
 
S p o ns or’s A ut h orize d 
Re prese nt ati ve  
 
 
 
 
 
 Si g n at ure  D ate  
E xec ute d si g n at ure p a ges are m ai nt ai ne d wit hi n t he Tri al M aster File  
 
V V- [ADDRESS_1083823] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083824] o x y pr o gester o ne A cetate F oll o wi n g a Si n gle S u bc uta ne o us A d mi nistrati o n of T V -4 6 0 4 6 i n 
Healt h y W o me n of Re pr o d ucti ve A ge  
Versi o n Date: 1 6  M arc h  2 0 2 1  
Pri nci p al I n vesti g at or:   
Title:   
A d dress of I n vesti g ati o n al Ce nter:   
  
  
Tel:   
I h a ve rea d t he pr ot oc ol wit h A me n d me nt [ADDRESS_1083825] 
(I M P) t hat were f ur nis he d t o me b y t he s p o ns or t o all p h ysicia ns a n d ot her st u d y pers o n n el 
re p orti n g t o me w h o  parti ci pate i n t his st u d y a n d will disc uss t his material wit h t he m t o e ns ure 
t hat t he y are f ull y i nf or me d re gar di n g t he I M P a n d t he c o n d uct of t he st u d y. I a gree t o kee p 
rec or ds o n all s u bject i nf or mati o n, I M P s hi p me nt a n d ret ur n f or ms, a n d all ot her i nf o r mati o n 
c ollecte d d uri n g t he st u d y, i n a cc or da nce wit h nati o nal a n d l ocal G o o d Cli nical Practice ( G C P) 
re g ulati o ns as well as all ot her nati o nal a n d i nter n ati o nal la ws a n d re g ulati o ns.  
Pri nci p al I n vesti g at or  
 
 Si g n at ure  D ate  
E xec ute d si g n at ure p a ges are m ai nt ai ne d wit hi n t he I n vesti g at or Site File a n d t he Tri al 
M aster File  
 
V V- [ADDRESS_1083826] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083827] u d y: T V [ADDRESS_1083828] u d y: A Ra n d o mize d, D ose -ra n ge Fi n di n g St u d y t o E v al uate P har mac o ki netics of 
Me dr o x y pr o gester o ne A c etate F oll o wi n g a Si n gle S u bc uta ne o us A d mi nistrati o n of T V -4 6 0 4 6 i n 
Healt h y W o me n of Re pr o d ucti ve A ge   
S p o ns or:  Te va Bra n de d P har mace utical Pr o d ucts R & D, I nc.  
I n vesti g ati o n al Ne w Dr u g (I N D) N u m ber: [ADDRESS_1083829] (I M P ):  de p ot me dr o x y pr o gester o ne acetate 
( D M P A [ T V -4 6 0 4 6])  
Acti ve S u bst a nce : me dr o x y pr o gester o n e acetate ( M P A)  
E u dr a Vi gil a nce ( E V) c o de f or t he I M P: N ot A p plic a ble  
T y pe of St u d y:  P har mac o ki netic ( P K) St u d y  
P h ase of Cli nic al De vel o p me nt:  [ADDRESS_1083830] a n ne d: [ADDRESS_1083831] a n ne d: U nite d States of A merica, D o mi nica n Re p u blic  
Pl a n ne d St u d y Peri o d: T he st u d y is e x pecte d t o start i n Q uarter 04 2 0 2 0 (first s u bject scree ne d) 
a n d ha ve a d urati o n peri o d  of a p pr o xi matel y 2 6 m o nt hs (t hr o u g h last s u bject o ut).  
Pri m ar y O bjecti ve(s): T he pri mar y o bje cti ve of t his st u d y is t o e v al uate a n d c o m pare t he 
p har mac o ki netic pr ofile of M P A f oll o wi n g s u bc uta ne o us a d mi nistrati o n of 3 d oses of T V -4 6 0 4 6 
3 0 0 m g/ m L ( 1 2 0 m g/ 0 . 4 m L; 1 8 0 m g/ 0. 6 m L; 2 4 0 m g/ 0. 8 m L), a n d 1 0 4 m g/ 0. 6 5 m L of De p o -
s u b Q Pr o vera i n he alt h y fe male s u bjects.  
Sec o n d ar y O bjecti ve(s):  T he sec o n d ar y o bje cti ves of t he st u d y are t o e val uate a n d c o m p are t he 
safet y, l ocal t olera bilit y, a n d acce pta bilit y of a s u b c uta n e o us i njecti o n of 3 d oses of  
T V -4 6 0 4 6 3 0 0 m g/ m L ( 1 2 0 m g/ 0. 4 m L; 1 8 0 m g/ 0. 6 m L; 2 4 0 m g/ 0. 8 m L) a n d 1 0 4 m g/ 0. [ADDRESS_1083832] u d y Desi g n a n d Met h o d ol o g y:  T his is a ra n d o mize d, partiall y -bli n de d d ose -ra n ge 
fi n di n g  st u d y t o e val uat e a n d c o m pare t he p har mac o ki netics of M P A, safet y, l oc al t olera bilit y, 
a n d acce pta bilit y of t he si n gle s u bc uta n e o us a d mi nistrati o n of 3 d oses of T V -4 6 0 4 6 3 0 0 m g/ m L 
( 1 2 0 m g/ 0. 4 m L, 1 8 0 m g/ 0. 6 m L or 2 4 0 m g/ 0. 8 m L), a n d 1 0 4 m g/ 0. [ADDRESS_1083833] of a scree ni n g p eri o d ( a p pr o xi matel y 1. 5 m o nt hs, or 6 wee ks), 
treat me nt i nitiati o n ( Da y 0) a n d f oll o w -u p ( u p t o 1 8 m o nt hs or 7 8 wee ks).  
 
V V- [ADDRESS_1083834] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083835] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 7 I n vesti g ati o n al Me dici n al Pr o d ucts (I M Ps): D ose, P h ar m ace uti c al F o r m, R o ute of 
A d mi nistr ati o n, a n d A d mi nistr ati o n R ate  
Test I M P:  T V -4 6 0 4 6 ( Me dr o x y pr o gester o ne acetate i njecta ble s us p e nsi o n 3 0 0 m g/ m L)   
Refere nce I M P: D e p o –s u b Q Pr o vera 1 0 4 ® ( Me dr o x y pr o gester o n e acetate i njecta ble 
s us pe nsi o n [ 1 0 4 m g/ 0. 6 5 m L f or s c use])  
St u d y P o p ul ati o n a n d N u m ber of S u bjects Pl a n ne d:  A p pr o xi matel y si xt y ( 6 0) h ealt h y fe m ale 
s u bjects of re pr o d ucti ve a ge at l o w ris k of pre g na nc y wit h n o c o ntrai n dicati o ns f or M P A -
c o ntai ni n g pr o d u cts will be ra n d o mize d t o 1 of 3 d oses of T V -4 6 0 4 6 3 0 0 m g/ m L ( 1 2 0, 1 8 0, 2 4 0 
m g) or 1 d os e of De p o -s u b Q Pr o vera ( 1 0 4 m g/ 0. 6 5 m L) ( a p pr o xi matel y 1 5 w o me n per gr o u p).  
D ur ati o n of S u bject P a rtici p ati o n:  T otal d urati o n of t he st u d y f or eac h s u bj ect is e x pecte d t o 
be a p pr o xi matel y [ADDRESS_1083836] u d y tr eat me nt i nitiati o n.  
M ai n Criteri a f or I ncl usi o n: S u bjects ma y be i n cl u de d i n t he st u d y o nl y if t he y m eet all of t he 
st u d y i ncl usi o n criteri a. T he mai n i ncl usi o n criteria are:  
a.  willi n g a n d ca pa ble of gi vi n g si g ne d i nf or me d c o nse nt  
b.  fe male of 1 8 t o 4 5 years of a ge (i n cl usi ve)  
c.  healt h y b ase d o n res ults of p h ysic al e x a mi nati o n, me dical hist or y, vital si g ns tests, 
a n d Pa p  s mear res ults  
d.  has re g ular m e nstr ual c ycle ( 2 1 t o 3 5 da ys)  
e.  has a l o w ris k of pre g na n c y (ie, steriliz e d, i n e x cl usi vel y sa me -se x part ners hi p, 
a bsti ne nt, i n m o n o ga m o us relati o ns hi p wit h vasect o mize d part ner, usi n g n o n -
h or m o nal i ntra uteri ne d e vice (I U D), or c o nsiste ntl y usi n g barrier met h o ds of 
c o ntrace pti o n)  
f.  ha d a n or mal ma m m o gra m wit hi n t he last year, if 4 0 years of a ge or ol d er  
g.  has a b o d y mass i n de x ( B MI) of 1 8 t o 3 5, i ncl usi ve  
h.  has he m o gl o bi n ≥ 1 0. 5 g/ d L  
i.  is willi n g a n d a ble t o c o m pl y wit h all st u d y re q uire me nts a n d ret ur n t o t he 
i n vesti gati o nal c e nter f or t he f oll o w -u p pr oce d ures a n d assess me nts as s pe cifie d i n 
t his pr ot oc ol  
M ai n Criteri a f or E xcl usi o n: S u bjects will be e xcl u de d fr o m partici pati n g i n t his st u d y if t he y 
meet a n y of t he st u d y e x cl usi o n  criteria. T h e mai n e x cl usi o n criteria are:  
a.  has h y p erte nsi o n wit h:  
○ s yst olic  bl o o d press ur e  (B P ) ≥ [ADDRESS_1083837] olic B P ≥ 1 0 0  m m H g  
○ vasc ular dise ase  
b.  has a n a b n or m al Pa p res ult t hat re q uires treat me nt or i n t he o pi [INVESTIGATOR_9384] o n of a n i n vesti gat or 
w o ul d ma ke st u d y p artici pati o n u nsafe or c o m plicate data i nter pretati o n   
V V- [ADDRESS_1083838] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083839] ors f or car di o v asc ular dise ase (e g, s m o ki n g, o b esit y, 
h y perte nsi o n, k n o w n l o w hi g h de nsit y li p o pr otei n [ H D L ], hi g h l o w de nsit y 
li p o pr otei n  [L D L ], or hi g h tri gl yceri de le vels)  
d.  has c urre nt or hist or y of isc he mic heart disease  
e.  has acti ve t hr o m b o p hle bitis, c urre nt or past hist or y of t hr o m b o e m b olic dis or ders, 
cere bral vas c ular dise ase or str o ke  
f.  has s yste mic l u p us er yt h e mat os us  
g.  has r he u mat oi d art hritis o n i m m u n os u p pressi ve t hera p y  
h.  has u ne x plai ne d va gi n al blee di n g  
i.  has dia betes  
j.  has str o n g fa mil y hist or y of breast c a ncer ( d efi ne d as o ne or m ore first de gree 
relati ves wit h breast ca n cer, breast ca n cer occ urri n g bef ore m e n o pa use i n t hree or 
m ore fa mil y me m bers, re gar dless of de gree of rel ati o ns hi p, a n d a n y male fa mil y 
me m ber wit h breast ca ncer), or  
k.  has c urre nt or hist or y of breast c a ncer, or u n dia g n ose d mass detecte d b y breast e x a m  
l.  has c urre nt or hist or y of cer vical ca n cer  
m.  has cirr h osis or li ver t u m ors  
n.  has o ne or m ore baseli ne li ver f u nct i o n test(s) o utsi de t he l ocal la b orat or y’s n or mal 
ra n ge  
o.  has k n o w n oste o p or osis or oste o pe nia  
p.  has hist or y of di a g n ose d cli nical de pressi o n or bi p olar dis or der, wit h or wit h o ut 
s uici dal i deati o n, a n d/ or hist or y of s uici de atte m pt, e x ce pt s h ort -li ve d sit uati o nal 
de pressi o n t hat di d n ot re q uire me dicati o n a n d h as n ot rec urre d i n last fi ve years  
q.  has hist or y of ps yc hiatric dis or der t hat i n t he o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or w o ul d ma ke 
st u d y partici p ati o n u nsafe, w o ul d i nterfere wit h a d here nce t o st u d y re q uir e me nts or 
c o m plicate data i nter pret ati o n  
r.  use d M P A -c o ntai ni n g i njecta ble pr o d u cts i n t he past [ADDRESS_1083840] 6  m o nt hs  
t.  use d a n y of t he f oll o wi n g me dicati o ns wit hi n 1 m o nt h pri or t o e nr oll me nt:  
○ a n y i n v esti gati o nal dr u g  
○ pr o hi bite d dr u gs p er pr ot oc ol  
○ oral c o ntrace pti ves, c o ntrace pti ve ri n g or patc h  
○ le v o n or gestrel i ntra ut eri n e s yste m ( L N G I U S) or c o ntrace pti ve i m pla nt  
u.  is partici pati n g i n a n ot her cli nical trial  
v.  is pre g n a nt  
w.  desires t o bec o me pre g n a nt i n s u bse q ue nt [ADDRESS_1083841] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083842] u gs per pr ot oc ol i n t he ne xt 1 2 m o nt hs  
aa.  has k n o w n se nsiti vit y t o M P A or i nacti ve i n gre die nts  
b b.  pla ns t o  m o ve t o a n ot her l ocati o n i n t he ne xt 1 2 m o nt hs  
cc.  has a n y c o n diti o n (s ocial or me dical), w hi c h i n t he o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or w o ul d 
ma ke st u d y p artici pati o n u nsafe, w o ul d i nterfere wit h a d here nce t o t he cli ni cal st u d y 
re q uire me nts or c o m plicate data i nter pretati o n  
St u d y E v al u ati o ns  
P h ar m a c o ki netic Assess me nts:  Bl o o d s a m ples ( a p pr o xi matel y 5 m L) will be c ollecte d bef ore 
a n d u p t o 5 2 wee ks ( 3 6 5 da ys) after I M P a d mi nistrati o n f or t he det er mi nati o n of ser u m M P A.  
S afet y Assess me nts:  Safet y a n d l ocal t olera bilit y e val uati o n will be base d o n t he f oll o wi n g:  
• occ urre nce of a d v erse e v e nts  
• use of c o nc o mita nt me di cati o n  
• c ha n ge i n vital si g ns a n d b o d y w ei g ht  
• va gi n al blee di n g patter n  
• c ha n ge i n m o o d  
• c ha n ge i n li ver f u ncti o n tests  
• Estra di ol ( E 2) le vels  
• dela ye d ret ur n t o o v ulati o n ( > 1 2 m o nt hs after treat me nt i nit iati o n) w here o v ulati o n is 
defi ne d as a si n gle pr o gester o ne ( P) ≥ 4. 7 n g/ m L  
• occ urre nce of i njecti o n site reacti o ns (I S Rs)  
Acce pt a bilit y assess me nts: Acce pta bilit y will be e val uat e d base d o n t he s u bject’s res p o nses t o 
acce pta bilit y q uesti o ns.  
St atistic al Met h o ds  
S a m ple Size D eter mi n ati o n: T he g oal of t he st u d y is t o select a d ose of T V -[ADDRESS_1083843] o n w hi c h t o base sa m ple siz e 
calc ulati o ns, 1 5 s u bjects per treat me nt gr o u p (a p pr o xi matel y 6 0 i n t otal) are e x pecte d t o be 
s ufficie nt t o i nf or m d ose selecti o n b ase d o n d ata fr o m rece nt P K st u dies of M P A deli vere d 
s u bc uta ne o usl y.  
T he i nte nt of t he st u d y is t o ha ve a mi ni m u m of [ADDRESS_1083844] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083845] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 1 0  P h ar m a c o ki netic Me as ures/ P a r a meters:  
T he f oll o wi n g pri mar y p har mac o ki netic  p ara m eters will be calc ulat e d fr o m c o nce ntr ati o n -ti me 
data:  
• ti me t o ma xi m u m o bser ve d ser u m dr u g c o nce ntr ati o n (t ma x ) 
• ma xi m u m o bser ve d ser u m dr u g c o nce ntr ati o n  ( C ma x ) 
• ser u m M P A c o nce ntr ati o ns at da y 9 1 ( C 9 1 ), da y 1 8 2 ( C 1 8 2 ), a n d da y 2 1 0 ( C 2 1 0 ) 
• area u n d er t he s er u m c o n ce ntrati o n -ti me c ur ve ( A U C) fr o m ti me 0 t o da y 1 8 2  
( A U C 0-1 8 2 ); A U C fr o m ti me 0 t o da y 2 1 0 ( A U C 0-2 1 0 ); a n d A U C e xtra p olate d t o 
i nfi nit y ( A U C 0-∞) 
• a p par e nt ter mi nal half -life (t ½) 
A n al yses  
P h ar m a c o ki netic A n al ysis:  N o n -c o m part me ntal met h o ds will be use d t o esti mate A U C val ues 
a n d t ½. T he ot her esti mates (t ma x , C ma x , C 9 1 , C 1 8 2 , a n d C 2 1 0 ) will be base d o n o bser ve d val u es 
w here p ossi ble. N o f or m al h y p ot hesis  tests of p har mac o ki netic dat a are pla n ne d. Para meter 
esti mates will be s u m mariz e d b y treat me nt gr o u p f or eac h d os e le vel usi n g descri pti ve statistics, 
i ncl u di n g n u m ber ( n), me a n, sta n dar d de viati o n ( S D), ge o metric m ea n, ge o metric c oefficie nt of 
variati o n , har m o nic mea n (f or t ½), me dia n, mi ni m u m, ma xi m u m, a n d ass ociate d 9 5 % c o nfi d e nce 
i nter vals ( CIs). Gra p hical dis pla ys will i ncl u de i n di vi d ual a n d ge o metric mea n p har mac o ki netics 
pr ofiles o n u n -tra nsf or me d a n d se mi -l o g ( base 1 0) data. Descri pti ve c o m paris o ns  of P K 
para meters bet wee n test a n d refere n ce gr o u ps will be base d o n ge o metric mea n rati os a n d 9 0 % 
CIs.  
S afet y Me as ure me nts:  
T he safet y me as ure m e nts f or t his st u d y i ncl u de:  
• occ urre nce of a d v erse e v e nts  
• use of c o nc o mita nt me di cati o n  
• vital si g ns a n d b o d y wei g ht meas ure me nt  
• va gi n al blee di n g patter n  
• assess me nt of m o o d b y Patie nt Healt h Q uesti o n naire -9 ( P H Q -9)  
• li ver f u ncti o n tests  
• E [ADDRESS_1083846] u d y  
• P meas ure me nts at W ee ks 4 8, 4 9, 5 0, 5 1, a n d 5 2  
• occ urre nce of I S Rs  
T he acce pta bilit y p ara m eters  are:  
• s u bject’s res p o nses t o acce pta bilit y q u esti o ns  
S afet y A n al ysis: N o f or mal h y p ot hesis tests of safet y d ata are pla n n e d. All safet y data will be 
s u m marize d b y treat me nt gr o u p usi n g des cri pti ve statistics ( n, mea n, S D, sta n dar d err or, m e dia n, 
V V- [ADDRESS_1083847] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083848] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 1 1  mi ni m u m, a n d ma xi m u m f or c o nti n u o us varia bl es, a n d fre q u e nc y a n d perce nta ge f or cate g ori cal 
varia bles). S pecificall y, t he n u m ber a n d p erce nta ge of s u bjects e x perie n ci n g treat me nt -e mer ge nt 
a d verse e ve nts will be prese nte d b y treat me nt gr o u p, o verall, b y se verit y gra de, a n d b y 
relate d ness t o tr eat me nt. A d verse e ve nts will be f urt her s u m mariz e d i n listi n gs or fre q u e nc y 
ta bles acc or di n g t o s yste m or ga n class a n d preferre d ter m. Seri o us a d verse e ve nts a n d a d v erse 
e ve nts lea di n g t o wit h dra wal fr o m t he st u d y will be liste d se parat el y. C o n c o mita nt me dicati o n 
use will be s u m mariz e d b y treat me nt  gr o u p i n fre q ue nc y ta bles, b y t hera pe utic class a n d 
me dici ne cate g or y. C ha n ge i n vital si g ns ( B P [s yst olic/ diast olic], p ulse, b o d y te m perat ur e a n d 
res pi[INVESTIGATOR_1313] o n) a n d b o d y wei g ht fr o m D a y [ADDRESS_1083849] ur ba nces 
(irre g ular va gi nal blee di n g or s p otti n g) will li ke wise be s u m mariz e d descri pti vel y a n d c o m pare d 
bet wee n tr eat me nt gr o u ps. M o o d data will be s u m mariz e d o ver ti me usi n g fre q ue n c y ta bles a n d 
gra p hical dis pla ys . Li ver f u ncti o n will be assesse d b y ta b ulati n g c h a n ge i n li ver f u ncti o n tests 
fr o m baseli ne t o Da y 7, Wee ks 1 3, 2 6, a n d 5 2. Rates of ret ur n t o o v ulati o n b y 1 2 m o nt hs ( Wee k 
5 2), w here o v ulati o n is defi ne d as a si n gle P  ≥ 4. 7 n g/ m L, will be pr o vi de d b y treat me nt gr o u p. 
Estra di ol c o nce ntr ati o ns will be s u m marize d f or eac h gr o u p usi n g mea ns, sta n dar d de viati o ns, 
a n d gra p hic al dis pla ys t hr o u g h Wee k 5 2. T he I S R data will be pr o vi de d b y gr o u p i n fre q u e nc y 
ta bles (if a p plica bl e) a n d usi n g s u bject -d ata listi n gs. T he res p o nses t o acce pta bilit y q u esti o ns will 
be descri pti vel y c o m p are d bet wee n tr eat me nt gr o u ps.  
V V- [ADDRESS_1083850] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083851] u d y D esi g n Rati o nale  ................................ ................................ ................. 2 2  
1. 4. 2.  D osa ge Rati o nale  ................................ ................................ ................................ ........ 2 2  
2.  S T U D Y O BJ E C TI V E S A N D M E A S U R E S/ P A R A M E T E R S  ................................ ... [ADDRESS_1083852] u d y O bjecti ves a n d Meas ures/ Para meters  ........................ [ADDRESS_1083853] u d y Pr oce d ures  ................................ ................................ ................................ ........ 2 7  
3. 4. 1.  Pr oce d ures f or Scree ni n g  ................................ ................................ ............................ 3 0  
3. 4. 2.  Pr oce d ures f or E nr oll me nt ( Da y 0)  ................................ ................................ ............. [ADDRESS_1083854] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083855]  ................................ ............................. 3 2  
4. 2.  Treat me nt of S u bjects  ................................ ................................ ................................ .3 2  
4. 3.  Bli n di n g/ U n bli n di n g  ................................ ................................ ................................ ... [ADDRESS_1083856] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083857] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083858] C o m plai nt  ................................ ................................ ............ 5 9  
1 1. 4.  Data Q ualit y C o ntr ol  ................................ ................................ ................................ ... 5 9  
1 1. 5.  A u dit a n d I ns pecti o n  ................................ ................................ ................................ ... 6 0  
1 2.  E T HI C A L A N D R E G U L A T O R Y C O N SI D E R A TI O N S  ................................ .......... 6 1  
1 2. 1.  Healt h A ut h orities a n d I n de pe n de nt Et hics C o m mittees/I nstit uti o nal Re vie w 
B oar ds  ................................ ................................ ................................ ......................... [ADDRESS_1083859] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083860] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 1 6  A P P E N DI X  A.  S T U D Y R E S P O N SI BI LI TI E S  ................................ ................................ .......... 8 3  
A P P E N DI X  B.  S P E CI M E N S A M P LI N G A N D H A N D LI N G  ................................ .................. 8 5  
LI S T O F T A B L E S  
Ta ble  1:  St u d y Pr oce d ures a n d Assess me nts  ................................ ................................ ............ 2 8  
Ta ble  2:  Tar get Ti me Wi n d o ws f or F oll o w -u p Visits  ................................ .............................. 3 1  
Ta ble  3:  I n v esti gati o nal Me dici nal Pr o d ucts Use d i n t he St u d y  ................................ ............... 3 3  
Ta ble  4:  A p pr o xi mate Bl o o d V ol u mes  ................................ ................................ ..................... [ADDRESS_1083861] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083862] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 1 7  LI S T O F FI G U R E S  
Fi g ure  1:  O verall St u d y Sc h e matic Dia gra m  ................................ ................................ ............. [ADDRESS_1083863] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083864] u g c o nce ntrati o n -ti me c ur ve  
A U C 0–1 8 2  area u n der t he ser u m c o nce ntr ati o n -ti me c ur ve fr o m ti me 0 t o da y 1 8 2  
A U C 0–2 1 0  area u n der t he ser u m c o nce ntr ati o n -ti me c ur ve fr o m ti me 0 t o da y 2 1 0  
A U C 0-∞  area u n der t he ser u m c o nce ntr ati o n -ti me c ur ve e xtra p olate d t o i nfi nit y  
B P  bl o o d press ure  
B MI  b o d y mass i n de x  
C D M S  cli nical data ma na ge me nt s yst e m  
C F R  C o de of Fe deral Re g ulati o ns ( U S)  
CI  c o ntrace pti ve i nj ecti o n  
C9 [ADDRESS_1083865] u g A d mi nistrati o n  
G C P  G o o d Cli nical Practice  
G L P  G o o d La b orat or y Practice  
H D L  hi g h de nsit y li p o pr otei n  
I B  I n vesti gat or’s Br oc h ure  
I C F  i nf or me d c o nse nt f or m  
I C H  I nter nati o nal C o nfere nce o n H ar m o nisati o n  
I E C  I n de p e n de nt Et hics C o m mitte e  
I M P  i n vesti gati o nal me dici nal pr o d uct  
I R B  I nstit uti o nal Re vie w B oar d  
I S R  I nj ecti o n site reacti o n  
I U D  i ntra uteri ne de vice  
V V- [ADDRESS_1083866] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083867] u d y Re vie w C o m mittee  
S U S A R  s us pecte d u ne x pecte d seri o us a d verse reacti o n  
t1/ [ADDRESS_1083868] u g c o nce ntrati o n  
U L N  u p per li mit of t he n or mal ra n ge  
U S( A)  U nite d States ( of A merica)  
V V- [ADDRESS_1083869] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083870] o x y pr o gester o ne acetate  ( D M P A), f or t he pre ve nti o n of pre g n a nc y w he n i njecte d e v er y 
6 m o nt hs. De p o -s u b Q Pr o vera 1 0 4 a n d De p o Pr o vera C o ntrace pti ve I nje cti o n ( CI ) are t he 
[ADDRESS_1083871] u gs f or t he T V -4 6 0 4 6 d e vel o p me nt pr o gra m. M ore d etaile d i nf or mati o n is 
pr o vi de d i n t he c ur re nt v ersi o n of t he I n v esti gat or’s Br oc h ure (I B).  
T he o bjecti ve of t his st u d y is t o e val uat e a n d c o m p are t he p h ar mac o ki netic pr ofile of 
me dr o x y pr o gester o ne acetate ( M P A), safet y a n d l ocal t olera bilit y, a n d acce pta bilit y f oll o wi n g 
s u bc uta ne o us a d mi nistrati o n of o ne of [ADDRESS_1083872] o x y pr o gester o ne acetate  / me dr o x y pr o gester o ne acet ate ( D M P A/ M P A) has bee n 
e xte nsi vel y i n v esti gate d i n a n u m ber of a ni mal s pe cies. C o nse q ue ntl y,  t h e n o ncli nical 
p har mac ol o g y a n d t o xic ol o g y pr ofiles of D M P A/ M P A ha ve bee n well esta blis he d. P u blis he d 
n o ncli nical p har ma c ol o gi cal a n d t o xic ol o gical st u dies e val uati n g n o ncli nic al bi ol o gical a n d 
t o xic ol o gical/t o xic o ki netic acti vities of D M P A are s u m mariz e d i n t he c urre nt versi o n of t he I B 
t o s u p p ort t he c o ntrace pti o n i n dicati o n f or T V -4 6 0 4 6.  
Te va’s c urre nt n o n cli nical t o xic ol o g y pr o gra m c o nsists of [ADDRESS_1083873] u dies: a G o o d 
La b orat or y Practice ( G L P) fe male ra b bit s u bc uta ne o us l ocal t olera n ce/ di sta nt tar get or ga n tiss ue 
e val uati o n wit h l o n g -t er m t o xic o ki netic st u d y ( St u d y  D S -2 0 1 5 -0 0 9); a G L P m uri ne l ocal l y m p h 
n o de assa y st u d y ( St u d y  D S -2 0 1 5 -0 1 7); a n o n -G L P m uri ne l ocal l y m p h n o de assa y st u d y 
( St u d y  D S -2 0 1 4 -0 6 4); a si n gle d ose n o n -G L P feasi bilit y  st u d y of s u bc uta n e o us i njecti o n ( St u d y 
D S -2 0 1 8 -0 0 8); a n d a n o n -G L P fe male ra b bit s u bc uta ne o us p har mac o ki neti c a n d gr oss 
t olera bilit y st u d y ( St u d y  D P -2 0 1 4 -1 3 5). T he res ults of t hese st u dies are s u m marize d i n t he 
c urre nt v ersi o n of I B.  
1. 2. 2.  Cli nic al St u dies  
1. 2. 2. 1.  Cli nic al P h ar m ac ol o g y St u dies  
T he p har mac o ki netics ( P K) of M P A f oll o wi n g a si n gle s u bc uta n e o us i njecti o n of u n dil ute d a n d 
sali ne dil ute d [ADDRESS_1083874] u d y w hic h i n cl u de d 1 2 
healt h y s u bjects ( St u d y T V 4 6 0 4 6 -W H -1 0 0 7 5). All s u bjects, e x ce pt 1 i n t he u n dil ute d T V -4 6 0 4 6 
gr o u p,  h a d ser u m M P A l e vels greater t ha n 0. 2 0 n g/ m L [ADDRESS_1083875] u g c o nce ntr ati o n  ( C ma x ) i n t he u n dil ute d T V -[ADDRESS_1083876] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083877] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 2 1  sali ne -dil ute d T V -4 6 0 4 6 gr o u p  were 0. 5 3 n g/ m L a n d 0. 9 7 n g/ m L, res p ecti v el y. Areas u n d er t he 
c o nce ntr ati o n c ur ve ( A U C 0-∞) of t he u n dil ute d T V -4 6 0 4 6 gr o u p  a n d t he s ali ne -dil ute d T V -4 6 0 4 6 
gr o u p were 9 4. 5 6 da ys * n g/ m L a n d 1 1 4. 1 3 da ys * n g/ m L, res p ecti vel y. All e val ua ble s u bjects i n 
t he u n dil ute d  
T V -[ADDRESS_1083878] i n t he sali ne -dil ute d T V -4 6 0 4 6 gr o u p ha d ser u m M P A 
c o nce ntr ati o ns e x cee di n g 0. 1 0 n g/ m L o n Da y [ADDRESS_1083879] u d y T V 4 6 0 4 6 -W H -1 0 0 7 5. T he safet y d ata i n dicate d t hat treat me nt 
wit h 1 2 0 m g T V -4 6 0 4 6 was well t olerat e d. N o deat h, treat me nt rel ate d seri o us a d verse e ve nt 
( S A E), or wit h dra wal d u e t o a d vers e e ve nt ( A E) occ urre d i n t his st u d y. T wel ve ( 1 0 0 %) of t he [ADDRESS_1083880] u d y, t he maj orit y of w hi c h ( 8 0. 4 %) occ urre d wit hi n 7. 5 m o nt hs of treat me nt 
i nitiati o n. I nj ecti o n site reacti o n (I S R) w as t he m ost fre q ue ntl y re p orte d A E ( 9 [ 7 5. 0 %] s u bjects). 
T he rate of I S Rs ass ociat e d wit h s u bc uta ne o us i nj ecti o n of T V -[ADDRESS_1083881] u d y were mil d, tra nsie nt, a n d res ol ve d wit h o ut se q uelae. T w o s u bjects de vel o pe d s ki n 
disc ol orati o n ( h y p o pi g m e ntati o n) at t he site of i nj ecti o n. O ne s u bject d e vel o pe d 
h y p o pi g me ntati o n a p pr o xi matel y [ADDRESS_1083882] u d y 
e xit a p pr o xi matel y o ne year after o ns et; t he ot her s u bject de vel o pe d h y p o pi g me ntati o n 
a p pr o xi matel y [ADDRESS_1083883] u d y desi g n, i ncl usi o n/e x cl usi o n criteria, a n d pr oce d ures ha ve b ee n 
de vel o pe d i n a ma n n er t o pr ote ct s u bject safet y. T he res ults of t his st u d y m a y facilitate t he 
de vel o p me nt of a n e w l o n ger -acti n g i njecta ble c o ntrace pti ve.   
V V- [ADDRESS_1083884] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083885] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 2 2  1. 3. 2.  K n o w n a n d P ote nti al Ris ks of T V -4 6 0 4 6  
S pecific ris ks f or T V -4 6 0 4 6 i ncl u de t he ris k of p ossi ble s ki n disc ol orati o n (i ncl u di n g 
h y p o p i g me ntati o n). A d diti o nal i nf or mati o n re gar di n g ris ks t o s u bjects ma y be f o u n d i n t he I B.  
1. 4.  St u d y Desi g n R ati o n ale  
1. 4. 1.  Ge ner al St u d y Desi g n R ati o n ale  
T his is a ra n d o mize d, partiall y -bli n de d d ose -ra n ge fi n di n g st u d y t o e val uat e a n d c o m pare t he 
p har mac o ki netics of  M P A, safet y a n d l o cal t olera bilit y, a n d acce pta bilit y of t he si n gle 
s u bc uta ne o us a d mi nistrati o n of 3 d oses of T V -4 6 0 4 6 3 0 0 m g/ m L ( 1 2 0 m g/ 0. 4 m L,  
1 8 0 m g/ 0. 6 m L, or a n d 2 4 0 m g/ 0. 8 m L), a n d 1 0 4 m g/ 0. [ADDRESS_1083886] of a scree ni n g p eri o d ( a p pr o xi matel y  1. 5 m o nt hs, or 6 wee ks), 
treat me nt i nitiati o n ( Da y 0), a n d at least 5 2 w ee ks of f oll o w -u p. S u bjects wit h u nres ol ve d I S R(s) 
at W ee k 5 2 will be f oll o we d e ver y 3 m o nt hs t hr o u g h t he res ol uti o n of I S R(s) or Wee k [ADDRESS_1083887] u d y a n d 
ra n d o ml y assi g n e d i n a 1: 1: 1: [ADDRESS_1083888] u d y treat me nts: 1 2 0 m g/ 0. 4 m L, 
1 8 0  m g/ 0. 6  m L or 2 4 0 m g / 0. 8 m L of T V -4 6 0 4 6, or 1 0 4 m g/ 0. 6 5 m L of De p o -s u b Q Pr o vera 1 0 4 
(a p pr o xi matel y 1 5 w o me n per gr o u p). After tr eat me nt i nitiati o n, s u bjects will be f oll o we d f or 
5 2  wee ks a n d pr o vi de bl o o d sa m ples f or M P A, pr o gester o ne ( P, a n d estra di ol  ( E 2) as s h o w n i n 
Ta ble  1. 
I n a d diti o n t o fre q ue nt la b orat or y visits t here will be f o ur sc h e d ule d f oll o w -u p visits at W ee k 1 
( Da y 7), Wee k [ADDRESS_1083889] u d y is desi g n e d t o e val uate a n d c o m pare t he p har mac o ki netics of M P A, safet y a n d l o cal 
t olera bilit y, a n d acce pta bilit y of t h e si n gl e s u bc uta ne o us a d mi nistrati o n of o ne 3 d oses of  
T V -4 6 0 4 6 3 0 0 m g/ m L ( 1 2 0 m g/ 0. 4 m L, 1 8 0 m g/ 0. 6 m L or 2 4 0 m g/ 0. 8 m L) or 1 0 4 m g/ 0. [ADDRESS_1083890] e d d ose ra n ge of T V -4 6 0 4 6 w as c h ose n t o ha ve a hi g h pr o ba bilit y of brac k eti n g t h e 
d ose necess ar y t o 1) t o ac hie ve a c o m para ble ge o metric mea n [ADDRESS_1083891] u g ( 0. 3 5 t o 0. 4 0 n g/ m L), a n d 2) t o e ns ure a l o w (e g, 5 % or 
less) ris k of ret ur n t o o v ulati o n wit hi n 7 m o nt hs of treat me nt i njecti o n. B ot h criteria are e x pecte d 
t o be met f or b y a d ose of T V -4 6 0 4 6 bet w ee n 1 2 0 m g/ 0. 4 m L a n d 2 4 0 m g/ 0. [ADDRESS_1083892] u d y T V 4 6 0 4 6 -W H -1 0 0 7 5  (NC T 0 2 8 1 7 4 6 4 ), St u d y 7 0 2 1 7 9 ( N C T 0 2 4 5 6 5 8 4 ), a n d t he 
V V- [ADDRESS_1083893] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083894] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 2 3  P K/ P D st u dies w hic h i nf or me d t he la bel f or De p o -s u b Q Pr o vera 1 0 4  (J ai n et al 2 0 0 4 , T o h et al 
2 0 0 4 ).  A d ose of T V -[ADDRESS_1083895] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083896] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 2 4  2.   S T U D Y O B J E C TI V E S A N D M E A S U R E S/ P A R A M E T E R S  
2. 1.  Pri m ar y a n d Sec o n d ar y St u d y O bjecti ves a n d Me as ures/ P ar a meters  
O bjecti ves  M e as ures/ P ar a meters  
T he pri m ar y o bjecti ve  of t his st u d y is 
t o e val uate a n d c o m pare t he 
p har mac o ki netic pr ofile of 
me dr o x y pr o gester o ne acetate  (M P A ) 
f oll o wi n g s u bc uta ne o us a d mi nistrati o n 
of 3 d oses of T V -4 6 0 4 6 3 0 0 m g/ m L 
( 1 2 0 m g/ 0. 4 m L; 1 8 0 m g/ 0. 6 m L; 2 4 0 
m g/ 0. 8 m L), a n d 1 0 4 m g/ 0. [ADDRESS_1083897] u d y:  
• Cma x  ( ma xi m u m o bser ve d ser u m c o nce ntrati o n)  
• Tma x  (ti me t o C ma x ) 
• Ser u m M P A c o nce ntrati o ns at treat me nt d a ys 9 1, 1 8 2, a n d 2 1 0 ( C 9 1 , 
C1 8 2 , C 2 1 0 ) 
• A U C 0-1 8 2  (area u n der t he ser u m dr u g c o nce ntrati o n -ti me c ur ve fr o m 
ti me 0 t o da y 1 8 2); A U C 0-2 1 0 ( A U C fr o m ti me 0 t o da y 2 1 0); a n d 
A U C 0-∞ ( A U C e xtra p olate d t o i nfi nit y)  
• A p pare nt ter mi nal  half -life (t ½) 
T he sec o n d ar y o bjecti ves  of t he st u d y 
are:  
1)  t o e val uate a n d c o m pare t he 
safet y a n d l ocal t olera bilit y of 
a s u bc uta ne o us i nj ecti o n of 3 
d oses of T V -4 6 0 4 6 3 0 0 
m g/ m L ( 1 2 0 m g/ 0. 4 m L; 1 8 0 
m g/ 0. 6 m L; 2 4 0 m g/ 0. 8 m L) 
a n d 1 0 4 m g/ 0. 6 5 m L of De p o -
s u b Q P r o vera 1 0 4 i n healt h y 
fe male s u bj ects.  
2)  t o e val uate t he acce pta bilit y of 
a s u bc uta ne o us i nj ecti o n of 
T V -4 6 0 4 6 o ver t he ra n ge of 
differe nt d oses.  T he safet y a n d l ocal t olera bilit y  meas ures/ para meters are:  
• occ urre nce of a d verse e ve nts  
• use of c o nc o mita nt me dicati o n  
• vital si g ns a n d b o d y wei g ht meas ure me nt  
• va gi nal blee di n g patter n  
• assess me nt of m o o d b y P atie nt Healt h Q uesti o n naire -9 ( P H Q -9)  
• li ver f u ncti o n tests  
• estra di ol ( E 2 ) meas ure me nts t hr o u g h o ut t he st u d y   
• pr o gester o ne ( P) meas ure me nts at W ee ks 4 8, 4 9, 5 0, 5 1, a n d 5 2  
• occ urre nce of i nj ecti o n site reacti o ns ( I S Rs )  
T he acce pta bilit y para meters are:  
• s u bj ect’s res p o nses t o acce pta bilit y q uesti o ns  
V V- [ADDRESS_1083898] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083899] u d y s c he matic dia gra m is prese nte d i n  Fi g ure  1.  
Fi g ure  1: O ver all St u d y Sc he m ati c Di a gr a m  
 
 
 
3. 2.  S u bject Eli gi bilit y  
Pr os pecti ve wai vers (e x ce pti o ns) fr o m st u d y eli gi bilit y criteria t o all o w s u bjects t o  e nter a st u d y 
are n ot gra nte d b y Te v a (see Secti o n  1 1. 1. 2 ).  
3. 2. 1.  S u bject I ncl usi o n Criteri a  
S u bjects ma y be i n cl u de d i n t he st u d y if t he y me et all of t h e f oll o wi n g criteria:  
a.  willi n g a n d ca pa ble of gi vi n g si g ne d i nf or me d c o nse nt  
b.  fe male of 1 8 t o 4 5 years of a ge (i n cl usi ve)  
c.  healt h y b ase d o n res ults of p h ysic al e x a mi nati o n, me dical hist or y, vital si g ns tests, 
a n d Pa p s mear res ults  
d.  has re g ular m e nstr ual c ycl e ( 2 1 t o 3 5 da ys)  
e.  has a l o w ris k of pre g na n c y (ie, steriliz e d, i n e x cl usi vel y sa me -se x part ners hi p, 
a bsti ne nt, i n m o n o ga m o us relati o ns hi p wit h vasect o mize d part ner, usi n g n o n -
h or m o nal i ntra uteri ne d e vice (I U D), or c o nsiste ntl y usi n g barrier met h o ds of 
c o ntrace pti o n)  
f.  ha d a n or mal ma m m o gra m wit hi n t he last year, if [ADDRESS_1083900] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083901] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 2 6  g.  has a b o d y mass i n de x ( B MI) of 1 8 t o 3 5, i ncl usi ve  
h.  has he m o gl o bi n ≥ 1 0. 5 g/ d L  
i.  is willi n g a n d a ble t o c o m pl y wit h all st u d y re q uire me nts a n d ret ur n t o t he 
i n vesti gati o nal c e nter f or t he f oll o w -u p pr oce d ures a n d assess me nts as s pe cifie d i n 
t his pr ot oc ol  
3. 2. 2.  S u bject E xcl usi o n Criteri a  
S u bjects will be e x cl u de d fr o m partici pati n g i n t his st u d y if t he y meet a n y of t he f oll o wi n g 
criteria:  
a.  has h y p erte nsi o n wit h:  
○ s yst o lic B P ≥ [ADDRESS_1083902] olic B P ≥ 1 0 0  m m H g  
○ vasc ular dise ase  
b.  has a n a b n or m al Pa p res ult t hat re q uires treat me nt or i n t he o pi [INVESTIGATOR_9384] o n of a n i n vesti gat or 
w o ul d ma ke st u d y p artici pati o n u nsafe or c o m plicate data i nter pretati o n   
c.  has m ulti ple ris k fact ors f or ca r di o v asc ular dise ase (e g, s m o ki n g, o b esit y, 
h y perte nsi o n, k n o w n l o w  hi g h de nsit y li p o pr otei n  (H D L ), hi g h l o w de nsit y 
li p o pr otei n ( L D L ), or hi g h tri gl yceri de le vels)  
d.  has c urre nt or hist or y of isc he mic heart disease  
e.  has acti ve t hr o m b o p hle bitis, c urre nt or p ast hist or y of t hr o m b o e m b olic dis or ders, 
cere bral vas c ular dise ase or str o ke  
f.  has s yste mic l u p us er yt h e mat os us  
g.  has r he u mat oi d art hritis o n i m m u n os u p pressi ve t hera p y  
h.  has u ne x plai ne d va gi n al blee di n g  
i.  has dia betes  
j.  has str o n g fa mil y hist or y of breast c a ncer ( d e fi ne d as o ne or m ore first de gree 
relati ves wit h breast ca n cer, breast ca n cer occ urri n g bef ore m e n o pa use i n t hree or 
m ore fa mil y me m bers, re gar dless of de gree of relati o ns hi p, a n d a n y male fa mil y 
me m ber wit h breast ca ncer)  
k.  has c urre nt or hist or y of breast  ca ncer, or u n dia g n ose d mass detecte d b y breast e x a m  
l.  has c urre nt or hist or y of cer vical ca n cer  
m.  has cirr h osis or li ver t u m ors  
n.  has o ne or m ore baseli ne li ver f u ncti o n test(s) o utsi de t he l ocal la b orat or y’s n or mal 
ra n ge  
o.  has k n o w n oste o p or osis or oste o pe nia  
p.  ha s hist or y of di a g n ose d cli nical de pressi o n or bi p olar dis or der, wit h or wit h o ut 
s uici dal i deati o n, a n d/ or hist or y of s uici de atte m pt, e x ce pt s h ort -li ve d sit uati o nal 
de pressi o n t hat di d n ot re q uire me dicati o n a n d h as n ot rec urre d i n last fi ve years  
V V- [ADDRESS_1083903] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083904] 6  m o nt hs  
t.  use d a n y of t he f oll o wi n g me dicati o ns wit hi n 1 m o nt h pri or t o e nr oll me nt:  
○ a n y i n v esti gati o nal dr u g  
○ pr o hi bite d dr u gs p er pr ot oc ol  
○ oral c o ntrace pti ves, c o ntrace pti ve ri n g or patc h  
○ le v o n or gestrel i ntra ut eri n e s yste m or c o ntrace pti ve i m pla nt  
u.  is partici pati n g i n a n ot her cli nical trial  
v.  is pre g n a nt  
w.  desires t o bec o me pre g n a nt i n s u bse q ue nt [ADDRESS_1083905] u gs per pr ot oc ol i n t he ne xt 1 2 m o nt hs  
aa.  has k n o w n se nsiti vit y t o M P A or i nacti ve i n gre die nts  
b b.  pla ns t o  m o ve t o a n ot her l ocati o n i n t he ne xt 1 2 m o nt hs  
cc.  has a n y c o n diti o n (s ocial or me dical), w hi c h i n t he o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or w o ul d 
ma ke st u d y p artici pati o n u nsafe, w o ul d i nterfere wit h a d here nce t o t he cli ni cal st u d y 
re q uire me nts or c o m plicate data i nter pretati o n  
3. 3.  D ur ati o n of S u bject P artici p ati o n  
T otal d urati o n of t he st u d y f or eac h s u bject is e x pecte d t o be a p pr o xi matel y  [ADDRESS_1083906] 5 2 wee ks aft er treat me nt 
i nitiati o n.  If s u bjects ha v e u nres ol ve d I S R(s) at W ee k [ADDRESS_1083907] u d y pr oce d ures a n d ass ess me nts wit h t heir ti mi n g are s u m mariz e d i n Ta bl e  1. Detaile d 
descri pti o ns of eac h assess me nt are pr o vi de d i n S ecti o n  5 (safet y assess me nts) a n d Secti o n  6 
( p har mac o ki netic assess me nts).  
V V- [ADDRESS_1083908] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083909] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 2 8  T a ble  1: St u d y Pr oce d ures a n d Assess me nts  
Pr o ce d ures a n d 
assess me nts  Scree ni n g  E nr oll me nt  F oll o w -U p  
( 6 Wee ks bef ore 
R a n d o miz ati o n)  D a y 0  D a y 1 t o Wee k 5 2  
( D a y 3 6 5)  Wee ks 
6 5 a n d 
7 8  
  Sc he d ule d 
F oll o w -u p 
( D a y  7, Wee ks 
1 3, 2 6, a n d 5 2)  L a b 
visits a   
I nf or me d c o ns e nt  X     
Me dical hist or y  X     
I n cl usi o n a n d 
e x cl usi o n criteria  X X    
De m o gra p hics, 
c o ntrace pti ve a n d 
re pr o d ucti ve 
hist or y  X     
Hei g ht  X     
Vital si g ns 
meas ure me nt  X X X   
B o d y wei g ht  X X X   
P h ysical e x a m  X     
Uri ne pre g n a nc y 
test b  X X X X 
Ra n d o mizati o n   X    
St u d y dr u g 
a d mi nistrati o n   X    
E [ADDRESS_1083910] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083911] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 2 9  Pr o ce d ures a n d 
assess me nts  Scree ni n g  E nr oll me nt  F oll o w -U p  
( 6 Wee ks bef ore 
R a n d o miz ati o n)  D a y 0  D a y 1 t o Wee k 5 2  
( D a y 3 6 5)  Wee ks 
6 5 a n d 
7 8  
  Sc he d ule d 
F oll o w -u p 
( D a y  7, Wee ks 
1 3, 2 6, a n d 5 2)  L a b 
visits a   
C o nc o mita nt 
me dicati o n 
i n q uir y f  X X   X 
He m o gl o bi n  X     
Li ver f u ncti o n 
testi n g g X  X    
M o o d e val uati o n h  X X  X  
Va gi nal blee di n g 
patter n i   X   
Ma m m o gra m j X     
Pa p s mear k X     
Acce pt a bilit y l    X   
a S u bj ects will ret ur n f or la b orat or y visits at pre -defi ne d ti me p oi nts: Da ys 0, 1, 2, 3, 5, 7, 1 0, 1 2, 1 4, 1 8, 2 1, a n d 2 8; 
W ee ks 6, 8, 1 0, 1 2, 1 3, 1 5, 1 7, 1 9, 2 1, 2 3, 2 5, 2 6, 2 8, 3 0, a n d 3 2; a n d t he n e ver y [ADDRESS_1083912] will be perf or me d o n Da y 0; W ee ks 2 6, 3 2, 3 6, 4 0, 4 4, 4 8, a n d 5 2; a n d at W ee ks 6 5 a n d 
7 8 if a p plica ble, a n d at a n y ot her ti mes w he n i n dicate d.  
c Bl o o d sa m ples f or P a n d E 2 will be c ollecte d at Da y 0 a n d at W ee ks 4 8, 4 9, 5 0, 5 1, a n d 5 2. Bl o o d sa m ples f or E 2 
will b e c ollecte d at all visits w he n M P A or P is teste d starti n g o n Da y 2 8.  
d Bl o o d sa m ples f or M P A will be c ollecte d o n Da ys 0, 1, 2, 3, 5, 7, 1 0, 1 2, 1 4, 1 8, 2 1, a n d 2 8; W ee ks 6, 8, 1 0, 1 2, 
1 3, 1 5, 1 7, 1 9, 2 1, 2 3, 2 5, 2 6, 2 8, 3 0, a n d 3 2; a n d t he n e ver y 2 8 da ys t hr o u g h W ee k 5 2.  
e I S Rs will b e e val uate d o n Da y 0  i m me diatel y (ie, as s o o n as p ossi ble b ut n o later t ha n 1 0 mi n utes u p o n re m o vi n g 
t he nee dle) a n d 1 h o ur ( ± 5 mi n utes) after i nj ecti o n ; Da y 7; at W ee ks 1 3, 2 6, a n d 5 2 a n d at ot her visits, if i n dicate d. 
S u bj ects w h o ha ve I S R(s) at W ee k 5 2 will be f oll o we d e ver y 3 m o nt hs (at W ee ks 6 5 a n d 7 8) u ntil I S R res ol uti o n 
or W ee k [ADDRESS_1083913]. A d verse e ve nts a n d use of c o nc o mita nt me dicati o ns will als o be 
e val uate d d uri n g a d diti o nal I S R f oll o w u p at W ee ks 6 5 a n d 7 8.  
g Li ver f u ncti o n testi n g will b e d o ne at Scree ni n g, Da y 7 a n d at t he W ee ks 1 3, 2 6, a n d 5 2.  
h M o o d will b e e val uate d o n Da ys 0 a n d 2 8; W ee ks 8, [ADDRESS_1083914] t hat are wit hi n A merica n 
C olle ge of O bstetricia ns a n d G y nec o l o gists  ( A C O G) P a p test sta n dar d of care re q uire me nts. If a d diti o nal testi n g is 
V V- [ADDRESS_1083915] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083916] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 3 0  re q uire d base d o n P a p res ults, t his s h o ul d be c o m plete d pri or t o e nr oll me nt (i n acc or da nce wit h C o m mittee o n 
Practice B ulleti ns G y nec ol o g y 2 0 1 6 ).  
l Acce pta bilit y data will be c ollecte d at W ee ks 2 6 a n d 5 2.  
E 2 = Estra di ol; I S R =i nj ecti o n site reacti o n; La b = la b orat or y; M P A = me dr o x y pr o gester o ne acetate; P = Pr o gester o ne  
3. 4. 1.  Pr o ce d ures f or Scree ni n g  
A si g ne d a n d date d i nf or me d c o nse nt f or m (I C F) will be o btai ne d bef ore s cree ni n g pr oce d ures 
c o m me nce (s ee Secti o n  1 2. 2 ).  
After i nf or m e d c o nse nt is o btai ne d, s u bjects will be assi g n e d a s u bject i de ntificati o n n u m ber i n 
c o nsec uti ve or der wit hi n eac h i n vesti gati o nal c e nt er.  
De m o gra p hic d ata as w ell as c o ntrace pti ve a n d re pr o d ucti ve hist or y will be c ollecte d a n d 
d oc u me nte d. Scree ni n g f or eli gi bilit y  will i ncl u de , re vie w of eli gi bilit y criteria  a n d  me dical 
hist or y, meas ure me nt of he m o gl o bi n a n d li ver e nz y m es, a n d p h ysi cal e x a mi nati o n t hat will 
i ncl u de, at mi ni m u m: hea d/ nec k, ears, e yes, n os e, t hr oat, c hest a n d l u n gs, car di o vasc ular, 
a b d o me n, s ki n, l y m p h n o des a n d breast assess me nts. B MI will be cal c ulate d base d o n t he 
meas ure d w ei g ht a n d hei g ht.  
 
 
 I n a d diti o n, a ma m m o gra m will be perf or me d f or 
w o me n [ADDRESS_1083917] g ui deli nes ( C o m mittee o n Practice B ulleti ns G y nec ol o g y  2 0 1 6 ). I n 
a d diti o n, i n vesti gati o nal ce n ters ma y p erf or m a d diti o nal scree ni n g pr oce d ures per t heir sta n dar d 
of care pr oce d ures (e g, S TI t esti n g, uri n e dr u g scree ni n g). All scree ni n g pr oce d ures a n d tests will 
be c o m plete d wit hi n 6 w ee ks bef ore ra n d o mizati o n.  
3. 4. 2.  Pr o ce d ures f or E nr oll me nt  ( D a y 0)  
E nr o ll me nt visits will be sc he d ule d t o occ ur d uri n g t he first [ADDRESS_1083918] u d y a n d ra n d o ml y assi g n e d i n a 1: 1: 1: [ADDRESS_1083919] u d y treat me nts: 1 2 0 m g/ 0. 4 m L, 1 8 0 m g/ 0. 6 m L or 2 4 0 m g/ 0. 8 m L of T V -
4 6 0 4 6, or 1 0 4 m g/ 0. [ADDRESS_1083920] of a 
si n gle s u bc uta n e o us i njecti o n i n t he a b d o me n. T he i njecti o n site l ocati o n will be mar ke d a n d 
p h ot o gra p he d f or refere n ce. T he i njecti o n site will be o bser ve d f or I S Rs i m me diatel y (ie, as s o o n 
as p ossi ble b ut n o later t ha n 1 0 mi n utes u p o n re m o vi n g t he nee dle) a n d 1 h o ur ( ± 5 mi n utes) after 
t he i njecti o n .  
3. 4. 3.  Pr o ce d ures f or F oll o w -U p  
St u d y f oll o w -u p will last f or at least 5 2 w ee ks fr o m treat me nt i nitiati o n. T here will be f o ur 
sc he d ule d f oll o w -u p visits at W ee k 1 ( Da y 7), Wee k [ADDRESS_1083921] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083922] u d y  at pr e -defi ne d ti me p oi nts ( See Ta ble  1). Uri ne pre g na n c y tests 
will be a d mi nistere d peri o dicall y starti n g at W ee k [ADDRESS_1083923] u d y.  
I n a d diti o n t o t he sc he d ul e d f oll o w -u p visits, s u bjects will ret ur n f or la b orat or y visits t o pr o vi de 
bl o o d sa m ples f or M P A, P, a n d E 2 at pre -d efi ne d ti me p oi nts (see Ta ble  1).  
If t he s u bject has n e w or o n g oi n g I S Rs at W ee k 5 2, s he will be f oll o we d e ver y 3 m o nt hs (at 
Wee ks 6 5 a n d 7 8) u ntil I S R res ol uti o n or M o nt h 1 8 ( Wee k 7 8), w hic h e ver is earlier. If t he 
s u bject d oes n ot ha ve a n y I S Rs at W ee k [ADDRESS_1083924] ca n n ot atte n d a visit wit hi n t he tar get wi n d o w bel o w, t he visit pr oce d ures s h o ul d be 
c o n d ucte d as s o o n as p ossi ble re gar dless of ti mi n g.  
T a ble  2: T ar get Ti me Wi n d o ws f or F oll o w -u p Visit s  
T ar g et visit d ate  T ar g et ti me wi n d o w  
Da ys 1, 2  ± 1 h o ur  
Da ys 3, 5, 7  ± 3 h o urs  
Da ys 1 0, 1 2, 1 4, 1 8  ± [ADDRESS_1083925] Da y 2 1  ± [ADDRESS_1083926]’s re q u est or as dee me d necessar y b y t he i n vesti gat or.  
U nsc he d ule d pr o ce d ures ma y i ncl u d e t he f oll o wi n g:  
• c o nc o mita nt me dicati o n re vie w  
• vital si g ns meas ur e me nts  
• ad verse e ve nt i n q uir y  
• st u d y c o m plia nce re vi e w  
• uri ne pre g n a nc y test  
Ot her pr oce d ures m a y be perf or me d at t he discreti o n of t he i n vesti gat or a n d i n c o ns ult wit h t he 
s p o ns or.  
V V- [ADDRESS_1083927] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083928]  
A p pr o xi matel y 6 0 s u bj ects will be ra n d o mize d i n a 1 : 1: 1: [ADDRESS_1083929] u d y 
treat me nts: 1 2 0 m g/ 0. 4 m L, 1 8 0 m g/ 0. 6 m L or 2 4 0 m g/ 0. 8 m L of T V -4 6 0 4 6, or 1 0 4 m g/ 0. [ADDRESS_1083930] ( I M P ). F or t his st u d y, 
De p o -s u b Q Pr o vera  1 0 4 will be s u p plie d as a si n gle -u nit d ose of 1 0 4 m g/ 0. 6 5 m L prefille d glass 
s yri n ges pre -p ac k a ge d wit h 2 6 ga u ge 3/ 8” nee dle. Detaile d c o m p ositi o n a n d i njecti o n 
i nstr ucti o ns are c o ntai n e d i n t he De p o -s u b Q Pr o vera  1 0 4 Pres cri bi n g I nf or mati o n ( De p o -s u b Q 
Pr o vera 1 0 4 U S Prescri bi n g I nf or mati o n 2 0 1 6 ).  
4. 2.  Tre at me nt of S u bjects  
T V -[ADDRESS_1083931] 5  da ys of t he me nstr ual c ycl e usi n g a 2 3  ga u ge 3/ 8  i nc h nee dle 
f oll o wi n g t he s p o ns or’s i nstr ucti o ns f or a d mi nisteri n g a s u b c uta ne o us i nje cti o n. T he cli nical staff 
pre pari n g t he d os e a n d pr o vi di n g t he i n jecti o ns will be trai ne d t o s hiel d t he s yri n ge fr o m vie w of 
t he s u bject a n d a n y bli n d e d st u d y staff pri or t o a n d at t he ti me of i njecti o n.  
 
V V- [ADDRESS_1083932] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083933] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 3 3  T a ble  3: I n vesti g ati o n al Me dici n al Pr o d ucts Us e d i n t he St u d y  
I M P n a me  T V -[ADDRESS_1083934] o x y pr o gester o ne acetate i nj ecta ble 
s us pe nsi o n 3 0 0 m g/ m L  De p o –S u b Q Pr o vera 1 0 4 ® 
Me dr o x y pr o gester o ne acetate i nj ecta ble 
s us pe nsi o n ( 1 0 4 m g/ 0. 6 5 m L f or sc use)  
F or m ul ati o n  
 Me dr o x y -pr o gester o ne 
Acetate  [ADDRESS_1083935] o x y -
pr o gester o ne acetate  1 0 4 m g  
D oc usate s o di u m  0. 6 0 m g  Met h yl para b e n  1. 0 4 0 m g  
P ol yet h yle ne gl yc ol 
3 3 5 0  2 0. 0 0 m g  Pr o p yl para b e n  0. 0 9 8 m g  
S o di u m s ulfate a n h.  1 3. 0 0 m g  S o di u m C hl ori de  5. 2 0 0 m g  
M o n o basic s o di u m 
p h os p hate a n h.  0. 6 0 m g  P ol yet h yle ne Gl yc ol  1 8. 6 8 8 m g  
Di basic S o di u m 
p h os p hate a n h.  0. 2 3 m g  P ol ys or bate 8 0  1. 9 5 0 m g  
L-Met hi o ni ne  1. 5 0 m g  M o n o basic S o di u m 
P h os p hate ∙ H 2O 0. 4 5 1 m g  
W ater f or I nj ecti o n ( u p 
t o 1 m L)  qs  Di basic S o di u m 
P h os p hate ∙ 1 2 H 2O 0. 3 8 2 m g  
N A  N A  Met hi o ni ne  0. 9 7 5 m g  
N A  N A  P o vi d o ne  3. 2 5 0 m g  
N A  N A  W ater f or i nj ecti o n  
( u p t o 0. 6 5 m L)  qs  
U nit d ose 
stre n gt h(s)/ D os a ge 
le vel(s)  1 2 0 m g/ 0. 4 m L  
1 8 0 m g/ 0. 6 m L  
2 4 0 m g/ 0. 8 m L  1 0 4 m g/ 0. 6 5 m L  
R o ute of a d mi nistr ati o n  
 S C i nj ecti o n  S C i nj ecti o n  
a n h =a n h y dr o us; H2O = water; I M P = i n vesti gati o nal me dici nal pr o d uct; I N N = i nter nati o nal n o n pr o prietar y na me; 
N A = n ot a p plica ble; qs = q ua ntit y s ufficie nt; S C =s u bc uta ne o us  
4. 3.  Bli n di n g/ U n bli n di n g  
T his st u d y will be partiall y -bli n de d d ue t o differe nces i n a p peara n ce a n d v ol u me of t he 
treat me nts. Desi g nate d u n bli n de d st u d y staff wi ll c o n d uct ra n d o mizati o n pr oce d ures. T he staff 
pre pari n g a n d a d mi nisteri n g st u d y i njecti o ns will be u n bli n de d b ut will be trai ne d t o s hiel d t he 
s yri n ge pri or t o a n d at t h e ti me of i njecti o n fr o m vie w of t he s u bject a n d a n y ot her bli n de d st u d y 
staff. F HI  [ADDRESS_1083936] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083937] u d y p h ar mac y 
ma n ual.  
F or a d v erse e ve nts t hat are defi n e d as a S us pecte d U ne x pecte d Seri o us A d verse Reacti o n 
( S U S A R) (ie, reas o na ble p ossi bilit y t hat a d v erse e ve nt is relate d t o treat me nt; Secti o n  5. 2. 5 ), 
Gl o bal Patie nt Safet y a n d P har mac o vi gila nce will re q uest t hat t he treat me nt c o de be re veal e d t o 
c o m pl y wit h re g ul at or y re q uire me nts. T he re p ort will be pr o vi de d i n a n u n bli n de d ma n ner  f or 
re g ulat or y s u b missi o n. I n t he case of a S U S A R, o nl y t he s p o ns or a n d a desi g nat e d u n bli n de d 
F HI 3 6 0 staff will recei v e t he u n bli n de d re p ort f or re g ulat or y s u b missi o n; ot her staff will recei ve 
a bli n de d re p ort i n a cc or da nce wit h s p o ns or's c urre nt pr oce d ures . 
All cases of i na d v erte nt u n bli n di n g will be ha n dle d per F HI 3 6 0’s sta n d ar d o perati n g pr oce d ures  
( S O Ps).  
4. 4.  St o p pi n g R ules a n d Disc o nti n u ati o n Criteri a  
If, at a n y ti me o ne of t he f oll o wi n g occ urs: t w o or m ore I S Rs gra de d as se v ere a d v erse e ve nts, 1 5 
cases of s ki n disc ol or ati o n at i njecti o n site (e g, h y p o pi g me ntati o n) o n g oi n g f or m ore t ha n [ADDRESS_1083938] u d y Re vie w C o m mittee ( S R C), wi ll occ ur, at w hic h ti me a 
rec o m me n dati o n ma y b e ma de t o pa use e nr oll me nt or halt t he st u d y. Ot her pla n ne d re vie ws will 
ta ke place as sc h e d ule d (see Secti o n  9. 8 ), at w hi c h ti me t he S R C c o ul d a d vise t hat t he st u d y st o p 
or be m o difie d base d o n c o ncer ns f or safet y of s u bjects or defi niti ve c o n cl usi o ns.  
Si nce m ost of t he st u d y dr u gs are e x pecte d t o re m ai n i n t he b o d y m o nt hs after i njecti o n, st u d y 
disc o nti n ua ti o n will n ot be t he sa me as tr eat me nt disc o nti n uati o n. St u d y st aff will e x plai n t o 
s u bjects w h o wis h t o disc o nti n ue t he st u d y earl y t h at it is i m p orta nt t o sta y i n t he st u d y u ntil 
safet y assess me nts are c o m plete d. H o we ver, a s u bject ma y disc o nti n ue partic i pati o n i n t he st u d y 
at a n y ti me f or a n y reas o n (e g, wit h dra w al of c o ns e nt or a n a d v erse e ve nt) wit h o ut l oss of ot her 
be nefits or ser vices t o w hic h t he y m a y be e ntitle d. All s u bjects w h o disc o nti n ue earl y will be 
f oll o we d acc or di n g t o S u bject Wit h dra wal Cr iteria a n d Pr oce d ures ( Secti o n  4. 9. 1 ). Reas o ns f or 
disc o nti n uati o n fr o m t he st u d y will be rec or de d o n t he a p pr o priat e electr o nic case re p ort f or m 
(eC R F ) 
Ot hers reas o ns t he st u d y ma y b e st o p pe d i ncl u de:  
• I nstit uti o nal Re vie w B oar d ( I R B )/ I n de p e n de nt Et hics C o m mittee ( I E C ) rec o m me n d 
ter mi nati n g t he st u d y  
• T he F o o d a n d Dr u g A d mi nistrati o n ( F D A ) re q uests t hat t he st u d y be disc o nti n ue d or 
place d o n h ol d.   
• T he s p o ns or  deci d es t o re d uce t he sc o p e (e g, re d uce sa m ple siz e, dr o p o ne or m ore 
st u d y gr o u ps) or ter mi nat e t he st u d y. T h e s p o ns or ma y ter mi nate t he st u d y at a n y ti me 
f or a n y reas o n.  
V V- [ADDRESS_1083939] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083940] Wit h dra wal Criteria a n d Pr oce d ures ( Secti o n  4. 9. 1 ).   
4. 5.  I nteri m D at a Re vie ws  
T he st u d y will be o v ersee n b y a n i nter nal S R C, t he c o m p ositi o n a n d res p o nsi bilities of w hic h 
will be detaile d i n a se parate S R C O perati o nal Pla n.  E xter nal c o ns ulta nts wit h rele va nt 
s pecialties ma y als o be e n ga ge d as part of t his S R C . 
T he S R C will c o n ve ne f or at least o ne re vie w of i nteri m data after  at least 8 0 % of s u bjects ha v e 
ha d a c h a nce t o c o m plete 7. [ADDRESS_1083941] u d y. I n a d diti o n, u n pla n ne d 
re vie ws ma y b e tri g gere d b y t h e o cc urre nce of I S Rs, i njecti o n site disc ol orati o n 
( h y p o pi g me ntati o n) e ve nts a n d/ or seri o us a n d relate d a d vers e e ve nts. At t h e ti me of a n y pla n ne d 
or u n pla n ne d i nteri m re vi e w of data, t h e S R C ma y rec o m me n d t hat t he trial be m o difie d or 
halte d t o e ns ure t he  s afet y a n d well -bei n g of st u d y s u bjects. T here will be n o a dj ust me nt t o t y p e I 
err or t o acc o u nt f or a n y i nteri m re vie ws of st u d y d ata.  
4. 6.  Pri or a n d C o nc o mit a nt T her a p y or Me dic ati o n  
A n y pri or or c o n c o mita nt me dicati o n a s u bject  has ha d wit hi n [ADDRESS_1083942] u d y: a mi n o gl utet hi mi de; ster oi d 
h or m o nes (estr o ge ns, pr o gesti ns a n d a n dr o ge ns); a n d a ntiretr o viral dr u gs i n cl u di n g  n o n -
n ucle osi de re v erse tr a nscri ptase i n hi bit ors (efa vir e nz a n d ne vira pi [INVESTIGATOR_050]) a n d rit o na vir -b o oste d 
pr otease i n hi bit ors. T he use of pr o hi bite d dr u gs will be d oc u me nte d as a n i m p orta nt pr ot oc ol 
de viati o n. I n a d diti o n, a p plicati o n of ba n da ges t o i njecti o n site s will be disc o ura ge d.  
4. 7.  Pr oce d ures f or M o nit ori n g S u bject C o m pli a nce  
All I M Ps will be i njecte d b y t he i n vesti gat or or ot her cli nical pers o n nel at t he i n vesti gati o nal 
ce nter; t heref ore, m o nit ori n g of s u bj ect c o m plia nce will n ot be necess ar y.  
4. 8.  T ot al Bl o o d V ol u me  
T he t otal v ol u me of bl o o d t o be c ollecte d f or eac h s u bject i n t his st u d y is a p pr o xi matel y [ADDRESS_1083943] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083944] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 3 6  T a ble  4: A p pr o xi m ate Bl o o d V ol u mes  
Assess me nts  V ol u me per s a m ple ( m L)  T ot al n u m ber of s a m ples  T ot al v ol u me ( m L)  
P har mac o ki netics  M P A: a b o ut 5 m L  3 2  1 6 0 m L  
Cli nical la b orat or y  He m o gl o bi n: a b o ut 5 m L  
Li ver e nz y mes: a b o ut 5 m L  
P: a b o ut 5 m L  
E 2: a b o ut 5 m L  
 He m o gl o bi n: 1  
Li ver e nz y mes: 5  
P: 6  
E 2: 2 5  He m o gl o bi n: 5 m L  
Li ver e nz y mes: 2 5 
m L  
P: 3 0 m L  
E 2: 1 2 5 m L  
A p pr o xi m ate T ot al   6 9  3 4 5 m L  
M P A: Me dr o x y pr o gester o ne acetate  
4. 9.  Wit h dr a w al of S u bjects  
4. 9. 1.  S u bject Wit h dr a w al Criteri a a n d Pr o ce d ures  
I n acc or da n ce wit h t he D eclarati o n of Helsi n ki, eac h s u bject is free t o wit h dra w fr o m t he st u d y at 
a n y ti me. T h e i n vesti gat or als o has t he ri g ht t o wit h dra w a s u b je ct fr o m t he st u d y i n t he e ve nt of 
i nterc urre nt ill ness, a d verse e ve nts, pre g na nc y (see Secti o n  5. 1 ) or ot her reas o ns c o ncer ni n g t he 
healt h or well -b e i n g of t he s u bject, or i n t he e v e nt of lac k of c o o perati o n.  
S h o ul d a s u bject deci de t o wit h dra w fr o m t he st u d y, or s h o ul d t he i n vesti gat or deci de t o 
wit h dra w t he s u bject, e ver y reas o n a ble eff ort will be ma de t o assess i nf or mati o n rele va nt t o t he 
e n d p oi nts  at t he ti me of disc o nti n uati o n. T his ma y i ncl u de b ut ma y n ot b e li mite d t o M P A 
testi n g, pre g n a nc y testi n g, ass ess me nt of I S Rs a n d/ or acce pta bilit y. T he fi nal visit pr oce d ures 
will be f oll o we d f or all s u bjects w h o  wit h dra w, if p ossi ble (see  Secti o n  3. 4 ).   
T he reas o n f or a n d date of wit h dra wal fr o m t he st u d y m ust be rec or de d o n t he s o urce 
d oc u me ntati o n a n d tra ns cri be d o nt o t he C R F. If a s u bject wit h dra ws c o ns e nt, e ver y atte m pt will 
be ma de t o deter mi ne t he reas o n.  
If t he i n vesti gat or det er mi nes t hat a n a d verse e v e nt is relate d t o t he test I M P, m o nit ori n g will 
c o nti n ue u ntil t he a d vers e e ve nt has res ol ve d or st a biliz e d, t he s u bject e xite d t he st u d y or t he 
s u bject has reac he d t h e e n d of t he f oll o w -u p peri o d. T he i n vesti gat or m ust i nf or m F HI [ADDRESS_1083945] u d y is o n g oi n g t he n s he will be c o nsi dere d 
“ pres u me d l ost t o f oll o w -u p”, b ut her file will re mai n o pe n u ntil st u d y cl ose o ut. If t he s u bject 
V V- [ADDRESS_1083946] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083947] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083948] u d y at 
t he ti me p oi nts liste d i n Ta ble  1: 
• occ urre nce of a d v erse e v e nts  
• use o f c o nc o mita nt me di cati o n  
• vital si g ns a n d b o d y wei g ht meas ure me nts  
• va gi n al blee di n g patter n  
• assess me nt of m o o d b y Patie nt Healt h Q uesti o n naire -9 ( P H Q -9)  
• li ver f u ncti o n tests  
• E [ADDRESS_1083949] u d y   
• P meas ure me nts at W ee ks 4 8, 4 9, 5 0, 5 1, a n d 5 2  
• occ urre nce of I S Rs  
5. 1. 1.  A d verse E ve nts  
I nf or mati o n o n a d verse e ve nts will be m o nit ore d t hr o u g h o ut t he st u d y as d etaile d i n Ta ble  1. 
D uri n g s c he d ule d f oll o w -u p  visits, st u d y staff will pr oacti vel y as k st u d y s u bjects a b o ut a n y ne w 
or w orse ni n g me dical iss ues si nce t he pre vi o us visit. At all ot her visits i nf or mati o n o n a d verse 
e ve nts will be rec or de d if self -re p orte d b y st u d y s u bjects.  
See Secti o n  5. [ADDRESS_1083950] u d y s u bjects. Details of pr o hi bite d me dicati o ns are f o u n d i n 
Secti o n  4. 6 .  
5. 1. 3.   Vit al Si g ns a n d B o d y Wei g ht Me as ure me nt  
Vital si g ns ( B P [s yst olic/ diast olic], te m perat ure, p ulse a n d res pir ati o n rate) a n d wei g ht will be 
meas ure d as detaile d i n  T a ble  1. 
Bef ore p ulse a n d B P are meas ure d, t he s u bject m ust be i n a s u pi [INVESTIGATOR_278161] -erect/seate d p ositi o n 
a n d resti n g f or at least [ADDRESS_1083951] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083952] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 3 9  p ote ntiall y cli nicall y si g nifica nt c ha n ge ( w ors e ni n g) fr o m Da y [ADDRESS_1083953] u d y ( Ta bl e  1). T o meas ure d e pressi o n or ps yc h ol o gi cal 
distress, a selecte d v ali date d scale bas e d o n t he 1 0 -ite m P H Q -9 ( Kr o e n ke  et al 2 0 0 1 ) will be use d 
t o ascertai n t he fre q u e nc y of a vari et y of s o matic a n d e m oti o nal i n dicat ors of well -bei n g a n d 
pr o d uce a n o v erall  sc ore f or t he se verit y of de pressi o n t hat will be c o m pare d bet wee n D a y [ADDRESS_1083954] u d y.  
5. 1. 6.  Li ver F u ncti o n Tests  
Li ver f u ncti o n testi n g will be perf or m e d b y t he i n v esti gati o nal c e nter la b orat or y as d etaile d i n 
Ta ble  1. 
T he f oll o wi n g t ests will be i ncl u de d i n t he li ver pa nel:  
• Al kali ne p h os p hatase ( A L P)  
• As partate a mi n otra nsferase ( A S T)  
• Ala ni ne a mi n otra nsf eras e ( A L T)  
• T otal pr otei n  
• Al b u mi n  
• T otal a n d direct bilir u bi n  
All occ urre nces of p ossi ble dr u g i n d u ce d li ver i nj ur y t hat me et H y’s la w criteria, defi n e d as all of 
t he bel o w, m ust be re p ort e d b y t h e i n vesti gat or t o t he s p o ns or as a s eri o us a d verse e v e nt:  
•  A L T or A S T i ncrease of > 3 x t he u p per li mit of n or mal ( U L N)  
• t otal bilir u bi n i ncrease of > 2 x U L N  
• a bse nce of i nitial fi n di n gs of c h olestasis (ie, n o s u bsta ntial i ncrease of A L P)  
5. 1. 7.  Estr a di ol Me as ure me nt  
All e nr olle d s u bjects will pr o vi de bl o o d f or E [ADDRESS_1083955] u d y, all s u bjects will ret ur n f or ser u m E 2 testi n g acc or di n g t o t he 
pre -defi ne d sc h e d ule ( T a ble  1). 
V V- [ADDRESS_1083956] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083957] u d y, all s u bjects will ret ur n f or ser u m P testi n g acc or di n g t o t he pre -defi ne d sc he d ule ( Ta ble  1).  
D uri n g t h e treat me nt p h ase of t he st u d y, if P is ≥ 4. 7  n g/ m L i n a si n gle sa m ple o v ulati o n will be 
c o nsi dere d c o nfir me d f or t he p ur p ose of t he  a nal ysis.  
5. 1. 9.  I njecti o n Site Re acti o ns  
I nje cti o n site reacti o n (I S R) will be e val uate d as detaile d i n  Ta ble  1. 
L ocal t olera bilit y will be assesse d b y occ urre nce of I S Rs i ncl u di n g b ut n ot li mite d t o er yt he ma 
(re d ness), s welli n g, pr urit us (itc hi n g), blee di n g, br uisi n g, i njecti o n site disc ol orati o n (e g, 
h y p o pi g me ntati o n), atr o p h y (ie, di m ple) or i njecti o n site pai n. F or t he p ur p ose of t his pr ot oc ol, 
i njecti o n  site pai n will i ncl u de pai n ass oci ate d wit h i njecti o n a n d a n y pai n or te n der ness 
at/ar o u n d t he i njecti o n site.  
T he site of i njecti o n will be e val uat e d f or p ossi ble I S Rs after t he i njecti o n at least t wice d uri n g 
t he i njecti o n visit i m me diatel y (i e, as s o o n  as p ossi ble b ut n o later t ha n 1 0 mi n utes u p o n 
re m o vi n g t he n ee dle) a n d 1 h o ur ( ± 5 mi n utes) after t he i njecti o n. I njecti o n sites will be 
m o nit ore d f or t he pr o gress of o n g oi n g a n d/ or o cc urre nce of ne w I S Rs. I f t he s u bject has ne w or 
o n g oi n g I S R at W ee k 5 2, s he will be f oll o we d e v er y 3 m o nt hs ( at W ee ks 6 5 a n d 7 8) u ntil I S R 
res ol uti o n or Wee k [ADDRESS_1083958]’s self -re p orts a n d 
vis ual e x a mi nati o n of t he site of i njecti o n b y bli n d e d st u d y staff. T he st u d y staff will be 
i nstr ucte d t o use n o n -lea di n g q uesti o ns (e g, “ D o y o u ha v e a n y n e w me dic al iss ues si nce pre vi o us 
visit? ”) f or I S R ascertai n me nt.  If t he s u bject r e p orts i njecti o n site pai n at a n y ti me d uri n g t he 
st u d y, s he will be as k e d t o assess t he pai n usi n g a n 1 1 -p oi nt N u meric Rati n g Scal e ( N R S) b y 
i n dicati n g a n u m b er bet w ee n 0 ( n o pai n) a n d 1 0 ( w orst pai n).  
All fi n di n gs will be rec or de d o n t he a p pr o priate st u d y C R Fs a n d cli nical n otes. P h ot os of t he 
i njecti o n site ma y be t a ke n t o s u p ple me nt d oc u me ntati o n of I S Rs a n y ti me d uri n g t he st u d y. All 
cases of i nje cti o n site disc ol orati o n ( h y p o pi g me nt ati o n) will be p h ot o gra p h e d. If necessar y, a 
c o ns ultati o n wit h a n a p pr o priate  cli nical e x pert ma y be s c he d ule d.  
T he f oll o wi n g I S Rs will be d oc u me nte d as a d verse e ve nts:  
• I nje cti o n site pai n wit h a n N R S sc ore of 7 t o 1 0  
• I nje cti o n site pr urit us/itc hi n g if itc hi n g l ocalize d t o t he i njecti o n site re q uiri n g ≥ 4 8 
h o urs of treat me nt O R ge neralize d itc hi n g ca usi n g i na bilit y t o p erf or m us u al s ocial 
a n d f u ncti o nal a cti vities  
• I nje cti o n site er yt he ma/r e d ness of  ≥ 5 c m i n dia met er ( or ≥ 2 5 c m 2 s urface area) or 
greater t ha n mi ni mal i nterfere nce wit h us ual s ocial a n d f u ncti o nal acti vities  
• I nje cti o n site i n d urati o n/s welli n g of ≥ 5 c m i n dia meter ( or ≥ 2 5 c m 2 s urface area) or 
greater t ha n mi ni mal i nterfere nce wit h us ual s ocial a n d f u ncti o nal acti vities  
V V- [ADDRESS_1083959] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083960] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 4 1  • A n y I S R t hat meets t he d efi niti o n of “seri o us a d v erse e ve nt ”  
5. 1. 1 0.  P h ysic al E x a mi n ati o ns  
P h ysical e x a mi n ati o n will be perf or m e d at scree ni n g t o defi n e i ncl usi o n/e x cl usi o n.   
5. 2.  S afet y Assess me nts  
5. 2. 1.  Defi niti o n of a n A d verse E ve nt  
A n a d vers e e ve nt is a n y u nt o war d me dical o cc urre nce i n a s u bject a d mi nistere d a p h ar mace utical 
pr o d uct, re gar dless of w h et her it has a ca usal r elati o ns hi p wit h t he treat me nt.  
I n t his st u d y, a n y a d v erse e ve nt occ urri n g aft er t he cli nical st u d y s u bject has si g ne d t he I C F 
t hr o u g h t he e n d of t he f oll o w -u p peri o d s h o ul d be rec or de d a n d re p orte d as a n a d vers e e v e nt. A n 
a d verse e ve nt oc c urri n g d u ri n g or after st u d y i njecti o n is referre d t o as a tr eat me nt e mer ge nt 
a d verse e ve nt  
A ne w c o n diti o n or t he w orse ni n g of a pre -e xisti n g c o n diti o n will be c o nsi dere d a n a d verse 
e ve nt. Sta ble c hr o nic c o n diti o ns (s uc h as art hritis) t hat are prese nt bef ore st u d y  e ntr y a n d d o n ot 
w orse n d uri n g t his st u d y will n ot be c o nsi dere d a d verse e v e nts.  
Acc or di n gl y, a n a d vers e e ve nt ca n i n cl u de a n y of t he f oll o wi n g:  
• i nterc urre nt ill nesses  
• p h ysical i nj uries  
• e ve nts p ossi bl y relate d t o c o nc o mita nt me dicati o n  
• si g nifica nt w orse n i n g (c h a n ge i n nat ure, s e verit y, or fre q u e nc y) of pre -e xisti n g 
c o n diti o ns ( N ote: A c o n diti o n rec or de d as pre -e xisti n g t hat is i nter mitte ntl y 
s y m pt o matic [e g, h ea d ac he] a n d t hat occ urs d uri n g t his  st u d y s h o ul d be rec or de d as 
a n a d vers e e v e nt.)  
• dr u g i nteract i o ns  
• e ve nts occ urri n g d uri n g dia g n ostic pr o ce d ures  
• la b orat or y or dia g n ostic t est a b n or malities, t hat res ult i n t he wit h dra wal of t he s u bject 
fr o m t he st u d y, are ass ociate d wit h cli nical si g ns a n d s y m pt o ms or a seri o us a d verse 
e ve nt, or re q uire me dical tre at me nt or f urt her dia g n ostic w or k -u p, or are c o nsi dere d 
b y t he i n vesti gat or t o b e cli nicall y si g nifica nt ( N ote: A b n or mal la b orat or y t est res ults 
at t he scree ni n g visit t hat precl u de a s u bject fr o m e nteri n g t he st u d y or recei vi n g 
st u d y treat me nt are n ot c o n si dere d a d v erse e ve nts.)  
• all e ve nts of p ossi ble dr u g i n d uc e d li ver i nj ur y ( Secti o n  5. 1. 6  ) 
• a n y p h ysi cal e x a mi nati o n, vital si g ns meas ur e me nt, electr ocar di o gra m, or ot her safet y 
assess me nt fi n di n g t hat is j u d ge d b y t he i n vesti gat or as a cli nic all y si g nifica nt c ha n ge 
( w orse ni n g) c o m pare d wit h a baseli ne val ue will be c o nsi dere d a n a d v erse e ve nt  
V V- [ADDRESS_1083961] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083962] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 4 2  • For t he p ur p os e of t his st u d y, irre g ular v a gi nal ble e di n g will n ot be c o nsi dere d a n 
a d verse e ve nt u nless it re q uires me dical i nter v e nti o n or meets t he defi niti o n of 
“seri o us a d verse e ve nt” ( See Secti o n  5. 2. 5 ).  
5. 2. 2.  Rec or di n g a n d Re p orti n g A d verse E ve nts  
F or a d v erse e ve nt r ec or di n g, t he st u d y peri o d is defi ne d f or eac h s u bject as t hat ti me peri o d fr o m 
si g nat ur e of t he I C F t hr o u g h t he e n d of t he f oll o w -u p per i o d. F or t his st u d y, t he f oll o w -u p peri o d 
is defi ne d as u p t o [ADDRESS_1083963] a b o ut a d v erse e v e nts b y as ki n g 
a n o pe n -e n d e d q uesti o n s uc h as, “ H a ve y o u h a d a n y u n us ual s y m pt o ms or me dical pr o ble ms 
si nce t he last visit? If yes, please des cri be.”  At all ot her visits i nf or mati o n o n a d verse e ve nts will 
be rec or de d if s elf -re p ort e d b y st u d y s u bjects. All o bser ve d or re p ort e d si g ns a n d s y m pt o ms will 
be rec or de d i n di vi d uall y, e x ce pt w he n c o nsi dere d ma nifestati o ns of a me di cal c o n diti o n or 
disease state. A precise dia g n osis will be rec or de d w he ne ver p ossi ble. W he n s uc h a dia g n osis is 
ma de, all relat e d si g ns, s y m pt o ms, a n d a n y test fi n di n gs will be rec or de d c ollecti vel y as  a si n gle 
dia g n osis o n t he C R F a n d, if it is a seri o us or pr ot oc ol defi ne d a d v erse e ve nt, o n t he Seri o us 
A d verse E v e nt F or m.  
T he cli nical c o urs e of eac h a d vers e e v e nt will be m o nit ore d at s uita ble i nter vals u ntil res ol ve d or 
sta bilize d or ret ur ne d t o basel i ne, t hr o u g h t he s u bject’s fi nal st u d y visit.  
T he o nset a n d e n d d ates a n d ti mes, acti o n ta ke n re gar di n g I M P, treat me nt a d mi nistere d, a n d 
o utc o me f or eac h a d vers e e ve nt m ust be rec or de d o n t he s o urce d o c u me ntati o n a n d tra nscri be d 
o nt o t he C R F.  
T he relati o ns hi p of eac h a d verse e ve nt t o I M P a n d st u d y pr oce d ures, a n d t h e se verit y a n d 
seri o us ness of eac h a d v erse e ve nt, as j u d ge d b y t h e i n vesti gat or, m ust be rec or de d as d escri b e d 
i n Secti o n  5. 2. [ADDRESS_1083964] be rec or de d as 1 of t he c h oices o n t he f oll o wi n g scale:  
Mil d:    N o li mitati o n of us ual acti vities  
M o der ate:  S o me li mitati o n of us ual acti vities  
Se vere:    I n a bilit y t o carr y o ut us u al acti vities  
V V- [ADDRESS_1083965] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083966] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 4 3  5. 2. 4.  Rel ati o ns hi p of a n A d verse E ve nt t o t he I M P  
T he relati o ns hi p of a n a d verse e v e nt t o t he I M P is c haracteriz e d as f oll o ws:  
Ter m  Defi niti o n  Cl arific ati o n  
N o reas o na ble 
p ossi bilit y  
( n ot relate d)  T his cate g or y a p plies t o a d verse 
e ve nts t hat, after caref ul 
c o nsi derati o n, are clearl y d ue t o 
e xtra ne o us ca uses ( disea se, 
e n vir o n me nt, etc.) or t o a d verse 
e ve nts t hat, after caref ul me di cal 
c o nsi derati o n at t he ti me t he y are 
e val uate d, are j u d ge d t o be 
u nrelate d t o t he I M P.  T he relati o ns hi p of a n a d verse e ve nt ma y be c o nsi dere d “ n o 
reas o na ble p ossi bilit y” if it is clearl y  d ue t o e xtra ne o us ca us es 
or if at least [ADDRESS_1083967] y:  
• It d oes n ot f oll o w a reas o na bl e te m p oral se q ue nce fr o m 
t he a d mi nistrati o n of t he I M P.  
• It c o ul d rea dil y ha ve bee n pr o d uce d b y t he s u bj ect’s 
cli nical state, e n vir o n me ntal, or t o xic fact ors, or ot her 
m o des of t hera p y a d mi nistere d t o t he s u bj ect.  
• It d oes n ot f oll o w a k n o w n patter n of res p o nse t o t he 
I M P.  
• It d oes n ot rea p pear or w orse n w he n t he I M P is 
re -a d mi nistere d.  
Reas o na ble 
p ossi bilit y  
(relate d)  T his cate g or y a p plies t o a d verse 
e ve nts f or w hic h, after caref ul 
me dical c o nsi derati o n at t he ti me 
t he y are e val uate d, a c o n necti o n 
wit h t he I M P a d mi nistrati o n 
ca n n ot b e r ule d o ut wit h 
certai nt y.  T he relati o ns hi p of a n a d verse e ve nt ma y be c o nsi dere d 
“reas o na ble p ossi bilit y” if at l east [ADDRESS_1083968] y:  
• It f oll o ws a reas o na ble te m p or al se q ue nce fr o m 
a d mi nistrati o n of t he I M P.  
• It ca n n ot b e reas o na bl y e x plai ne d b y t he k n o w n 
c haracteristics of t he s u bj ect’s cli nical state, 
e n vir o n me ntal or t o xic fact ors or ot her m o des of t hera p y 
a d mi nistere d t o t he s u bj ect.  
• It disa p pears or decreases o n cessati o n or re d ucti o n i n 
d ose. T here are i m p orta nt e xc e pti o ns w he n a n a d verse 
e ve nt d oes n ot disa p pear u p o n disc o nti n uati o n of t he I M P, 
yet a n I M P relati o ns hi p clearl y e xists.  
• It f oll o ws a k n o w n patter n of r es p o nse t o t he I M P.  
5. 2. 5.  Seri o us A d verse E ve nts  
5. 2. 5. 1.  Defi niti o n of a Seri o us A d verse E ve nt  
A seri o us a d verse e v e nt is a n a d vers e e ve nt o cc urri n g at a n y d os e t hat res ults i n a n y of t he 
f oll o wi n g o utc o mes or acti o ns:  
• deat h  
• a life -t hreate ni n g a d v erse e ve nt (ie, t he s u bject was at i m me diate ris k of deat h fr o m 
t he e ve nt as it occ urre d); d oes n ot i ncl u de a n e v e nt t hat, ha d it occ urre d i n a m ore 
se vere f or m, mi g ht h a ve ca use d deat h  
• i n patie nt h os pi[INVESTIGATOR_27967] o n or pr ol o n gati o n of e xisti n g h os pi[INVESTIGATOR_27967] o n, w hic h mea ns t hat 
h o s pi[INVESTIGATOR_307] i n patie nt a d missi o n a n d/ or pr ol o n gati o n of h os pi[INVESTIGATOR_70213] y w ere re q uire d f or 
treat me nt of a n a d vers e e ve nt, or t hat t he y occ urre d as a c o nse q u e nce of t he e ve nt. 
H os pi[INVESTIGATOR_1314] o ns sc he d ule d pri or t o st u d y e ntr y will n ot be c o nsi dere d seri o us a d verse 
e ve nts, u nless t here was w orse ni n g of t he pree xisti n g c o n diti o n d uri n g t he s u bject’s 
partici pati o n i n t his st u d y   
V V- [ADDRESS_1083969] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083970] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 4 4  • persiste nt or si g nifi ca nt disa bilit y or i nca p acit y (refers t o a s u bsta ntial disr u pti o n of 
o ne’s a bilit y t o c o n d u ct n or mal life f u ncti o ns)  
• a c o n ge nital a n o m al y/ birt h defect  
• a n i m p orta nt me dical e v e nt t hat ma y n ot res ult i n deat h, be life -t hreat e ni n g, or re q uire 
h os pi[INVESTIGATOR_27967] o n, b ut ma y j e o par dize t he s u bject a n d ma y re q uire m e dical i nter ve nti o n 
t o pre ve nt o ne of t h e o utc o mes liste d i n t his defi niti o n. E x a m ples of s uc h e ve nts are 
i nte nsi ve treat me nt i n a n e mer ge n c y r o o m or at h o me f or aller gi c br o nc h os pas m; 
bl o o d d yscrasias or c o n v ulsi o ns t hat d o n ot res ult i n h os pi[INVESTIGATOR_1314] o n; or t he 
de vel o p me nt of dr u g d e p e n de nc y or dr u g a b us e. N ote: A n y s us p ecte d tr a ns missi o n of 
a n i nfecti o us a ge nt via a me dici nal pr o d uct is c o nsi dere d a n i m p orta nt me dical e ve nt  
A n a d vers e e ve nt t hat d o es n ot meet a n y of t he criteria f or s eri o us ness liste d a b o ve will be 
re gar de d as a n o ns eri o us a d verse e ve nt.  
5. 2. 5. 2.  E x pecte d ness  
A seri o us a d verse e v e nt t hat is n ot i ncl u de d i n t he A d verse Reacti o n Secti o n  of t he rele v a nt 
refere nce safet y i nf or mati o n ( R SI) b y its s pecificit y, se v erit y, o utc o me, or fre q ue nc y is 
c o nsi dere d a n u ne x pecte d a d verse e ve nt. T he R SI f or t his st u d y is t he c urre nt I B f or  T V -4 6 0 4 6, 
a n d U S prescri bi n g i nf or mati o n f or De p o -S u b Q Pr o vera 1 0 4, De p o -Pr o vera CI a n d  
De p o Pr o vera 4 0 0 m g/ m L ( De p o -s u b Q  Pr o vera 1 0 4 U S prescri bi n g i nf or mati o n 2 0 1 6 , De p o -
Pr o vera  CI U S pr escri bi n g i nf or m ati o n 2 0 1 6 , a n d De p o -Pr o vera  Sterile A q ue o us S us pe nsi o n U S 
prescri bi n g i nf or mati o n 2 0 1 7 ).  
T he s p o ns or’s P har mac o vi gila nce De p art me nt will deter mi ne t he e x pecte d ness f or all seri o us 
a d verse e ve nts.  
F or t he p ur p os e of S U S A R re p orti n g, t he v ersi o n of t he I B at t he ti me of o cc urre nce of t he 
S U S A R a p plies.  
5. 2. 5. 3.  Seri o us A d verse E ve nt M a n a ge me nt Pl a n  
T he o bjecti ve of t h e Seri o us A d verse E v e nt Ma na ge m e nt Pla n ( S M P) is t o esta blis h t he 
res p o nsi bilities a n d pr oce d ures f or recei vi n g, pr ocessi n g, re p orti n g, rec o nciliati o n a n d f oll o wi n g 
u p of seri o us a d verse e v e nts.  T he S M P will be fi nalize d pri or t o st u d y i nitiati o n.  
5. 2. 5. 3. 1.  I n vesti g at or Res p o nsi bilit y  
All seri o us a d vers e e ve nts t hat occ ur d uri n g t he st u d y peri o d (i ncl u di n g t he pr ot oc ol defi ne d 
f oll o w -u p peri o d, re gar dl ess of j u d ge d rel ati o ns hi p t o treat me nt wit h t he st u d y dr u g), m ust be 
re p orte d t o t he s p o ns or b y t he i n vesti gat or p er t he pr oce d ures s pecifi e d i n t he S M P. T he e ve nt 
m ust be re p orte d wit hi n [ADDRESS_1083971] n ot be dela ye d, 
e ve n if n ot all t he i nf or m ati o n is a vaila ble.  
T he f oll o wi n g i nf or mati o n s h o ul d be pr o vi de d t o rec or d t he e ve nt a cc uratel y a n d c o m pletel y:  
• st u d y n u m ber  
• i n ves ti gat or a n d i n vesti gati o nal ce nter i d e ntificati o n  
V V- [ADDRESS_1083972] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083973] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 4 5  • s u bject i de ntificati o n n u m ber  
• o nset date a n d det aile d d escri pti o n of a d verse e v e nt  
• i n vesti gat or's ass ess me nt of t he relati o ns hi p of t he a d verse e ve nt t o t he st u d y dr u g ( n o 
reas o na bl e p ossi bilit y, reas o na ble  p ossi bilit y)  
A d diti o nal i nf or mati o n ma y i ncl u d e t he f oll o wi n g:  
• a ge a n d se x of s u bject  
• date of st u d y dr u g i njecti o n  
• acti o n ta ke n  
• o utc o me, if k n o w n  
• se verit y  
• e x pla nati o n of assess me nt of relate d n ess  
• c o nc o mita nt t hera p y (i ncl u di n g d oses, r o utes a n d re gi me ns) a n d tr eat me nt of t he 
e ve nt  
− perti ne nt la b orat or y or ot her dia g n ostic test data  
− me dical hist or y  
− f or a n a d v erse e ve nt r es ulti n g i n deat h:  
○ ca use of deat h ( w het her or n ot t he deat h was relat e d t o st u d y dr u g)  
○ a ut o ps y fi n di n gs (if a vail a ble)  
T he i n vesti gat or d oe s n ot nee d t o acti vel y m o nit or s u bjects f or a d v erse e ve nts o nce t heir f oll o w -
u p peri o d has e n d e d. Seri o us a d verse e ve nts oc c urri n g after st u d y disc o nti n uati o n will be 
re p orte d t o t he s p o ns or wit hi n [ADDRESS_1083974] u d y pr oce d ures.  
If a d diti o nal (f oll o w -u p) i nf or mati o n a b o ut a seri o us a d verse e ve nt be c o mes a vaila ble, t he 
i n vesti gat or will f or war d it t o t he s p o ns or wit hi n [ADDRESS_1083975] u d y e x ce pt f or 
a ut h orize d u n bli n de d staff. I n t he case of a S U S A R,  o nl y t he s p o ns or a n d a desi g nat e d u n bli n de d 
F HI 3 6 0 staff will recei v e t he u n bli n de d re p ort f or re g ulat or y s u b missi o n; ot her staff will recei ve 
a bli n de d re p ort.  
5. 2. 5. 3. 2.  S p o ns or Res p o nsi bilit y  
If a seri o us u ne x pecte d a d verse e v e nt is belie ve d t o be relate d t o t he  st u d y dr u g or st u d y 
pr oce d ures, t he s p o ns or will ta ke a p pr o priat e ste ps t o n otif y all i n vesti gat ors partici pati n g i n 
s p o ns ore d cli nical st u dies of T V -4 6 0 4 6 a n d t he a p pr o priate healt h a ut h orities a n d I R B/I E C, if 
a p pr o priate.  
V V- [ADDRESS_1083976] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083977] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 4 6  I n a d diti o n t o n otif yi n g t he i n vesti gat ors a n d healt h a ut h orities (a n d I R B/I E C, if a p pr o priate), 
ot her meas ur es ma y be re q uire d, i ncl u di n g t he f oll o wi n g:  
• a me n di n g t h e pr ot oc ol  
• disc o nti n ui n g or s us pe n di n g t he st u d y  
• i nf or mi n g c urre nt st u d y s u bjects of ne w fi n di n gs b y a m e n di n g t h e e xisti n g I C F  a n d 
re -c o ns e nti n g all s u bjects  
• m o dif yi n g listi n gs of e x pecte d t o xicities t o i ncl u de a d vers e e v e nts ne wl y i de ntifie d as 
relate d t o T V -[ADDRESS_1083978] I M P  a d mi nistrati o n 
will be cate g orize d as “ N o n -C o m plia nce t o I n vesti gati o nal Me di ci nal Pr o d uct ( I M P ).”  
T he f oll o wi n g are t y p es of me dicati o n err ors a n d s pecial sit uati o ns:  
• Me dicati o n err or: A n y u ni nte nti o nal err or i n t he prescri bi n g, dis pe nsi n g, or 
a d mi nistrati o n of a me dici nal pr o d uct w hile i n t he c o ntr ol of t he healt hcare 
pr ofessi o nal, patie nt, or c o ns u mer.  
• O ver d ose: A d mi nistrati o n of a q ua ntit y of a me di ci nal pr o d uct gi ve n per 
a d mi nistrati o n or c u m u lati vel y w hic h is a b o v e t he ma xi m u m rec o m me n de d d ose 
acc or di n g t o t he a ut h orize d pr o d uct i nf or mati o n. Cli nical j u d g me nt s h o ul d al wa ys be 
a p plie d. A n y d ose of I M P ( w het her t he test I M P, refere nce I M P, or pla ce b o I M P), 
w het her ta k e n i nte nti o nall y or u ni nte nt i o nall y, i n e x cess of t hat prescri be d m ust be 
i m me diatel y re p orte d t o t he s p o ns or.  
• Mis use: A n y i nte nti o nal t hera pe utic us e of a dr u g pr o d uct i n a n i na p pr o pri ate wa y or 
o pi [INVESTIGATOR_2495] d use c o ntrar y t o t he directe d or prescri be d patter n of use, re gar dless of t he 
pre se nce or a bs e nce of har m or a d v erse effects. E x a m ples: u n der usa ge, erratic or 
dis or ga niz e d use, i na p pr o priate use (f or a n xiet y), i n c o nj u ncti o n wit h alc o h ol or 
ille gal s u bsta nces, o ver us e.  
• A b use: A n y i nte nti o nal, n o nt hera pe utic us e of a dr u g pr o d uct or s u bsta n ce, e ve n 
o nce, f or t h e p ur p ose of ac hie vi n g a desir a ble ps yc h ol o gical or p h ysi ol o gic al effect, 
or i nte nti o nal use of t he o pi [INVESTIGATOR_2495] d f or a n o n me dical p ur p ose, s uc h as e u p h ori a or alteri n g 
o ne’s state of c o nsci o us n ess.  
• Off -la b el use: Sit uati o ns w here a n I M P  is i nte nti o nall y use d f or a me di cal p ur p ose n ot 
i n acc or da nce wit h t he a ut h orize d pr o d uct i nf or mati o n.  
• Occ u pati o nal e x p os ure: E x p os ure t o a n I M P, as a res ult of o ne’s pr ofessi o nal or 
n o n -pr ofessi o nal o cc u pati o n.  
V V- [ADDRESS_1083979] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083980] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 4 7  • Breastfee di n g: S us pect e d a d verse e ve nts w hic h o cc ur i n i nfa nts f oll o wi n g e x p os ure t o 
a me dici nal pr o d uct fr o m breast mil k.  
5. 2. 8.  Pr ot oc ol D e vi ati o ns Bec a use of a n A d verse E ve nt  
If a s u bject e x perie nces a n a d verse e ve nt or me di cal e mer ge n c y, de p art ures fr o m t he pr ot oc ol 
ma y b e all o we d o n a cas e -b y -case  basis. After sta biliz ati o n a n d/ or treat me n t has  bee n 
a d mi nistere d t o e ns ure s u bject safet y, t he i n v esti gat or or ot her p h ysicia n i n atte n da nce m ust 
c o ntact t he p h ysicia n i de ntifie d i n t he Cli nical St u d y Pers o n n el C o ntact I nf or mati o n secti o n  of 
t his pr ot oc o l (A p pe n di x  A) as s o o n as p ossi ble t o disc uss t he sit uati o n. T he i n vesti gat or, i n 
c o ns ultati o n wit h t he s p o ns or, will deci de w het h er t he s u bject s h o ul d c o nti n ue t o partici pate i n 
t he st u d y.  
5. 2. 9.  Pre g n a nc y  
T he ris k of pre g na nc y is mi ni mal d ue t o t he fact t hat o nl y w o me n w h o are at l o w ris k of 
pre g na nc y will be e nr olle d i n t he st u d y (see Secti o n  3. 2. 1  f or I ncl usi o n Criteria). O nl y w o m e n 
w h o are n ot pr e g na nt o n t he da y of t he st u d y i njecti o n a n d d o n ot wa nt t o bec o me pre g na nt i n t he 
ne xt [ADDRESS_1083981] pr o vi de t he s p o ns or wit h t he pre g na n c y f or m. T h e pr ocess f or re p orti n g 
a pre g na n c y is t he sa me as t hat f or re p orti n g a seri o us a d verse e ve nt b ut usi n g t he  pre g na nc y 
f or m. T he i n vesti gat or is n ot re q uire d t o re p ort s u bjects w h o are f o u n d t o be pre g na nt bet w ee n 
scree ni n g a n d e nr oll me nt.  
All s u bjects w h o bec o me pre g na nt will be m o nit ore d  f or t he o utc o m e of t he pre g na nc y 
(i ncl u di n g s p o nta n e o us, electi ve, or v o l u ntar y a b orti o n) . If t he pre g na nc y c o nti n ues t o ter m, t he 
o utc o me ( healt h of t h e i nfa nt u p t o 8  wee ks of a ge), i ncl u di n g det ails of birt h a n d prese n ce or 
a bse nce of a n y birt h defect, c o n ge nital a b n or m alities, or mater nal a n d ne w b or n c o m plicati o ns, 
will be  re p orte d t o t he s p o ns or. A n y c o m plicati o n of pre g na n c y d uri n g t he st u d y a n d a n y 
c o m plicati o n of pre g n a nc y t hat t he i n vesti gat or b ec o mes a ware of after wit h dra wal fr o m t he 
st u d y will be re p orte d as a n a d vers e e v e nt or seri o us a d verse e ve nt, as a p pr o priate.  
If t he pre g n a nc y i n t he w o ma n partici pati n g i n t he st u d y d oes n ot c o nti n ue t o ter m, 1 of t he 
f oll o wi n g acti o ns will be ta ke n:  
• F or a s p o nta n e o us a b orti o n, re p ort as a seri o us a d verse e v e nt.  
• F or a n electi ve a b orti o n d ue t o de vel o p me ntal a n o malies, re p ort as  a seri o us a d verse 
e ve nt.  
• F or a n electi ve a b orti o n n ot  d ue t o de vel o p me ntal a n o malies, re p ort o n t he pre g na nc y 
f or m; d o n ot re p ort as a n a d verse e ve nt.  
V V- [ADDRESS_1083982] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083983] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 4 8  6.  P H A R M A C O KI N E TI C  M E A S U R E M E N T S A N D A S S E S S M E N T S  
6. 1.  Ti mi n g of P h ar m ac o ki netic S a m pli n g  
Bl o o d sa m ples (a p pr o xi matel y 5 m L) will be o btai ne d via ve ni p u nct ure or i n d welli n g cat heter 
bef ore a n d t hr o u g h 5 2 w ee ks ( 3 6 5 da ys) aft er T V -4 6 0 4 6 a d mi nistrati o n f or deter mi nati o n of 
ser u m c o nce ntrati o n of M P A at t he ti me p oi nts detaile d i n Ta ble  1. S peci me n c ollecti o n, 
pr ocessi n g, a n d h a n dli n g re q uire me nts are d etaile d i n A p pe n di x  B. W he n t he p har mac o ki netic 
bl o o d sa m ple c ollecti o n c oi nci des wit h vital si g n assess me nt, assess me nt of vital si g ns s h o ul d 
prece d e p har mac o ki netic bl o o d sa m pli n g.  
6. 2.  P h ar m ac o ki netic P ar a meters  
T he f oll o wi n g p h ar mac o ki netic pa ra met ers will be calc ul ate d fr o m c o n ce ntrati o n -ti me data usi n g 
n o n -c o m part me ntal met h o ds, w he n p ossi ble:  
T he f oll o wi n g n o n -e x ha usti ve list of p har mac o ki n etic para m eters will be e val uate d t o s u p p ort t he 
pri mar y o bjecti ve of t h e st u d y:  
• Cma x  (ma xi m u m o bser ve d  ser u m dr u g c o n ce ntrati o n ) 
• Tma x  (ti me t o C ma x ) 
• Ser u m M P A c o nce ntr ati o ns at treat me nt da ys 9 1, 1 8 2, a n d 2 1 0 ( C 9 1 , C 1 8 2 , C 2 1 0 ) 
• A U C 0-1 8 2 (area u n d er t he ser u m dr u g c o n ce ntrati o n -ti me c ur ve fr o m ti me 0 t o da y 
1 8 2); A U C 0-2 1 0 ( A U C fr o m ti me 0 t o da y 2 1 0); a n d A U C 0-∞ ( A U C e xtra p olate d t o 
i nfi nit y)  
• A p pare nt ter mi nal half -life (t ½)  
V V- [ADDRESS_1083984] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083985] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083986] 
a b o ut t his met h o d, a n d w het her s he w o ul d us e t his met h o d i n t he f ut ure a n d/ or rec o m me n d it t o a 
frie n d.  
V V- [ADDRESS_1083987] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083988] o n w hic h t o base sa me size calc ulati o ns, 1 5 s u bjects per 
treat me nt gr o u p (a p pr o xi matel y 6 0 i n t otal) are e x pecte d t o be s ufficie nt t o i nf or m d ose selecti o n 
base d o n data fr o m rece nt P K st u dies of M P A deli vere d s u bc ut a ne o usl y.  
 
 
 
 
 
 
 
 
T he i nte nt of t he  st u d y is t o ha ve a mi ni m u m of [ADDRESS_1083989] u d y. A p pr o xi matel y 6 0 s u bjects will be ra n d o m iz e d i n a 
1: 1: 1: [ADDRESS_1083990] u d y usi n g a 
vali date d pr o gra m writte n i n S A S ®. 
F HI [ADDRESS_1083991] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083992] u g. S u bjects will be a nal yz e d acc or di n g t o treat me nt 
recei v e d, re gar dless of a n y all ocati o n err ors. T he S afet y A nal ysis Set will be use d f or all 
assess me nts of baseli ne, safet y, a n d acce pta bilit y data, as well as s e nsiti vit y a n al ys es of 
phar mac o ki netics d ata t h at i ncl u de all treat e d s u bjects, re gar dless of a n y e x cl usi o ns fr o m t he 
pri mar y p har mac o ki netics a nal ys es.  
9. 3. 4.  P h ar m a c o ki netic A n al ysis Set  
T he P har mac o ki n etic A n al ysis Set will be a s u bset of t he  Safet y A nal ysis Set, e x cl u di n g a n y 
s u bjec ts w h o ha d a b aseli ne M P A c o nce ntr ati o n t hat e x cee de d 5 % of t heir i n di vi d ual C ma x , ha d 
a n i m p orta nt pr ot oc ol de viati o n t hat ma y affect i nter pretati o n of t he M P A data, or faile d t o 
pr o vi de at least o ne e val u a ble p ost -treat me nt M P A s peci me n. T he a nal ysis set  will e x cl u de M P A 
data c ollecte d d uri n g ti me peri o ds w he n s u bj ects use d a c o nc o mita nt me di cati o n k n o w n t o 
i m pact t he p har mac o ki netics of M P A. I n t his a n al ysis set, s u bjects will be a nal yze d acc or di n g t o 
treat me nt recei ve d, re gar dless of a n y all ocati o n err o rs.  
9. 4.  D at a H a n dli n g C o n ve nti o ns  
Missi n g M P A c o nce ntr ati o ns at ke y ti me p oi nts (e g, start - a n d e n d -ti mes of partial areas u n der 
t he c o nce ntr ati o n -ti me c ur ve) will be i m p ute d, as a p pr o priate, usi n g met h o ds s pecifie d i n t he 
statistical a nal ysis pla n.  
9. 4. 1.  H a n dli n g W it h dr a w als a n d Missi n g D at a  
I n c o m plete a d v erse e ve nt o nset or c o nc o mita nt me dicati o n use dates ma y als o be i m p ute d or  
a dj u dicate d t o assess safet y or w h e n ce ns ori n g s u bjects fr o m  a nal ys es d ue t o pr o hi bite d 
me dicati o n use.  
N o ot her missi n g data will be i m p ute d u nless s pecifie d i n t he detaile d statistical a nal ysis pla n.  
9. 5.  St u d y P o p ul ati o n  
T his st u d y will recr uit healt h y s u bjects t o eli mi nat e c o nf o u n di n g fact ors (c o m or bi dities, 
c o me dicati o ns) wit h p ote ntial i m pact o n st u d y o utc o me. Si nce T V -[ADDRESS_1083993] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083994] Dis p ositi o n  
Data fr o m s u bjects scree ne d, s u bjects scree ne d b ut n ot ra n d o mize d a n d reas o n n ot ra n d o mize d, 
s u bjects w h o are ra n d o miz e d/e nr olle d, s u bjects ra n d o mize d/e nr olle d b ut n ot treate d a n d reas o n, 
p har mac o ki netic, a n d safet y a nal ysis sets, s u bjects w h o c o m plete t he st u d y, a n d s u bjects w h o 
wit h dra w fr o m t he st u d y will be s u m mariz e d usi n g des cri pti ve statistics. Data fr o m s u bjects w h o 
wit h dra w fr o m t he st u d y will als o be s u m marize d b y reas o n f or wit h dra w al usi n g descri pti ve 
statistics.  
9. 5. 2.  De m o gr a p hic s, C o ntr a ce pti ve a n d Re pr o d ucti ve Hist or y   
S u bject de m o gra p hi cs,  c o ntrace pti ve a n d re pr o d ucti ve hist or y  will be e x a mi ne d t o assess t he 
c o m para bilit y of t he treat me nts a n d will be s u m mariz e d usi n g descri pti ve statistics. F or 
c o nti n u o us varia bles, des cri pti ve statistics ( n u m ber [ n], mea n,  sta n dar d de viati o n  ( S D) , me dia n, 
mi ni m u m, a n d ma xi m u m) will be pr o vi de d. F or cate g ori cal varia bles, s u bje ct c o u nts a n d 
perce nt a ges will be pr o vi de d. Cate g ories f or missi n g dat a will be pres e nte d if necessar y.  
9. 6.  S afet y A n al ysis  
Safet y a nal yses will be perf or me d o n t h e safet y a n al ysis set. Safet y m eas ur es a n d ti me p oi nts are 
pr o vi de d i n Ta ble  1.  
Safet y a n d l ocal t olera bilit y e val u ati o n will be base d o n t he  f oll o wi n g:  
• occ urre nce of a d v erse e v e nts  
• use of c o nc o mita nt me di cati o n  
• c ha n ge i n vital si g ns a n d b o d y w ei g ht  
• va gi n al blee di n g patter n  
• c ha n ge i n m o o d  
• c ha n ge i n li ver f u ncti o n tests  
• E 2 le vels  
• dela ye d ret ur n t o o v ulati o n ( > 1 2 m o nt hs after treat me nt i nitia ti o n) w here o v ulati o n is 
defi ne d as a si n gle P  ≥ 4. 7 n g/ m L  
• occ urre nce of I S Rs  
N o f or mal h y p ot hesis tests of safet y data are pl a n ne d. All safet y dat a will be s u m mariz e d b y 
treat me nt gr o u p usi n g descri pti ve statistics ( n, mea n, S D, S E, me dia n, mi ni m u m, a n d m a xi m u m 
f or c o nti n u o us varia bl es, a n d fre q u e nc y a n d perce nta ge f or cate g ori cal vari a bles). S pecificall y, 
t he n u m ber a n d perce nta ge of s u bjects e x perie n ci n g treat me nt -e mer ge nt a d verse e v e nts will be 
V V- [ADDRESS_1083995] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083996] u d y will be liste d se pa ratel y. C o nc o mita nt me dicati o n use will be s u m mariz e d b y 
treat me nt gr o u p i n fre q ue nc y t a bles, b y t hera pe utic class a n d me dici ne cate g or y. C ha n ge i n vital 
si g ns ( B P [s yst olic/ diast olic], p ulse, b o d y t e m perat ure a n d res pi[INVESTIGATOR_1313] o n) a n d b o d y w ei g ht fr o m 
Da y [ADDRESS_1083997] ur ba nces (irre g ular 
va gi n al blee di n g or s p otti n g) will li ke wise be s u m mariz e d descri pti vel y a n d c o m pare d b et wee n 
t he test a n d refere nce gr o u ps. M o o d data will be s u m mariz e d o ver ti me fr o m Da y 0 usi n g 
fre q ue n c y ta bles a n d gra p hical dis pla ys. Li ver f u n cti o n will be assesse d b y ta b ulati n g c h a n ge i n 
li ver f u ncti o n tests fr o m baseli ne t o Da y 7, Wee ks 1 3, 2 6, a n d 5 2. Rat es of ret ur n t o o v ulati o n b y 
1 2 m o nt hs ( Wee k 5 2), w here o v ulati o n is defi ne d as a si n gl e P ≥ 4. 7 n g/ m L, will be pr o vi de d b y 
treat me nt gr o u p. Estra di ol c o nce ntrati o ns will be s u m marize d f or eac h gr o u p usi n g mea ns, 
sta n dar d de viati o ns, a n d gra p hical dis pla ys t hr o u g h Wee k 5 2. T he I S R data will be pr o vi de d b y 
gr o u p i n fre q u e nc y ta bles (if a p plica ble) a n d usi n g s u bject -data listi n gs.  
9. 7.  P h ar m ac o ki netic A n al ysis  
T he f oll o wi n g pri mar y p har mac o ki netic  p ara m eters will be calc ulat e d fr o m c o nce ntr ati o n -ti me 
data base d o n t he P har mac o ki netic A nal ysis Set:  
• ti me t o ma xi m u m o bser ve d ser u m dr u g c o nce ntr ati o n (t ma x ) 
• ma xi m u m o bser ve d ser u m dr u g c o nce ntr ati o n  ( C ma x ) 
• ser u m M P A c o nce ntr ati o n at da y 9 1 ( C 9 1 ), da y 1 8 2 ( C 1 8 2 ), a n d da y 2 1 0 ( C 2 1 0 ) 
•  A U C 0-1 8 2 (area u n d er t he ser u m dr u g c o n ce ntrati o n -ti me c ur ve fr o m ti me 0 t o da y 
1 8 2); A U C 0-2 1 0 ( A U C fr o m ti me 0 t o da y 2 1 0); a n d A U C 0-∞ ( A U C e xtra p olate d t o 
i nfi nit y)  
• a p pare nt ter mi nal half -life (t ½) 
A m o n g t hes e pri mar y p h ar mac o ki netics p ara m eters, n o n -c o m part me nt al met h o ds will be use d t o 
esti mate A U C val ues a n d t ½. T he ot her esti mates (t ma x , C ma x , C 9 1 , C 1 8 2 , a n d C 2 1 0 ) will be base d o n 
o bser ve d val u es w here p ossi ble. N o f or mal h y p ot hesis tests of p har mac o ki netic data are pla n n e d. 
Para meter esti mates will be s u m mariz e d b y tr eat m e nt gr o u p f or eac h d os e le vel usi n g d escri pti ve 
statistics, i ncl u di n g n, mea n, S D, sta n dar d err or , ge o metric mea n, ge o metri c c oefficie nt of 
variati o n, har m o nic mea n (f or t ½), me dia n, mi ni m u m, ma xi m u m, a n d 9 5 % c o nfi de nce i nter vals 
( CIs) f or mea ns. Gra p hic al dis pla ys will  i ncl u de i n di vi d ual a n d ge o metric mea n 
p har mac o ki netics pr ofiles.  
P K c o m paris o ns bet wee n eac h d ose of test f or m ul ati o n ( T V 4 6 0 4 6) a n d t he refere nce pr o d u ct 
( De p o -s u b Q Pr o v era 1 0 4) will be ma de bas e d o n ge o m etric mea n rati os (test/refere nce) a n d 9 0 % 
CIs wit h t he f oll o wi n g M P A e x p os ure para meters: Cma x , C 9 1 , C 1 8 2 , C 2 1 0 , A U C 0-1 8 2, A U C 0-2 1 0, a n d 
A U C 0-∞. 
Ot her p har m ac o ki netic p ara meters (e g, ste a d y -stat e tr o u g h c o nce ntrati o ns) ma y b e cal c ulate d 
usi n g n o n -c o m p art me ntal met h o ds or n o n -li near mi x e d effects m o dels t o i nf or m d ose sele cti o n.  
V V- [ADDRESS_1083998] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1083999] c h aracteristics (e g, B MI) o n p h ar mac o ki netics of M P A will li ke wise be 
e x pl ore d usi n g n o n -li near mi x e d effects m o dels as t he data per mits.  
9. 8.  Acce pt a bilit y A n al ysis  
T he res p o nses t o acce pta bilit y q u esti o ns at W ee ks [ADDRESS_1084000] 8 0 % of s u bjects ha ve ha d a c ha n ce 
t o c o m plete 7. [ADDRESS_1084001] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084002] urer’s dr u g pr o d uct s ti p ulati o n, i n a dr y pla ce, 
a n d i n a sec urel y l oc ke d, s u bsta ntiall y c o nstr uct e d ca bi net or e n cl os ure.  T V -[ADDRESS_1084003] ore d at c o ntr olle d r o o m te m perat ur e 2 0 ° C  t o 2 5° C ( 6 8 ° F  t o 7 7° F).  
T he i n vesti gat or m ust c o nfir m a p pr o priat e te m perat ure c o n diti o ns ha v e b ee n mai ntai ne d f or all 
I M Ps recei ve d. T he i n vesti gat or m ust re p ort a n d res ol ve a n y discre p a ncies b ef ore us e of t he 
I M Ps.  
[ADDRESS_1084004] ore d safel y a n d 
pr o perl y i n acc or da n ce wit h t he C F R or l ocal re g ulati o n s, a n d use d i n acc or da nce wit h t his 
pr ot oc ol.  
A rec or d of I M P acc o u nt a bilit y (ie, I M P a n d ot her materials recei ve d, us e d, retai ne d, ret ur ne d, or 
destr o ye d) m ust be pre pare d a n d si g ne d b y t he i n v esti gat or, wit h a n acc o u nt gi ve n f or a n y 
discre pa n cies. E m pt y  a n d partiall y us e d c o ntai ners of I M P will be destr o ye d at t he 
i n vesti gati o nal c e nter i n acc or da nce wit h i n vesti gati o nal ce nter S O Ps, wit h s p o ns or a p pr o val. I n 
t he e ve nt t he i n vesti gati o nal ce nter is u n a ble t o destr o y t he e m pt y a n d/ or u n use d u nits of I M P, 
t he I M P will be dis p ose d of, retai ne d, or ret ur n e d t o t he s p o ns or or desi g nee per F HI [ADDRESS_1084005] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084006] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 5 7  1 1.  Q U A LI T Y C O N T R O L A N D Q U A LI T Y A S S U R A N C E  
1 1. 1.  Pr ot oc ol A me n d me nts, Pr ot oc ol De vi ati o ns, a n d I m p ort a nt Pr ot oc ol 
De vi ati o ns  
1 1. 1. 1.  Pr ot oc ol A me n d me nts  
N o c ha n ges fr o m t he fi nal a p pr o ve d (si g ne d) pr ot o c ol will be i nitiate d wit h o ut t he pri or writte n 
a p pr o val or fa v ora ble o pi [INVESTIGATOR_9384] o n of a writte n a me n d me nt b y t he I R B/I E C a n d l ocal healt h 
a ut h orities, as a p plica ble, e x ce pt w he n necessar y t o a d dress i m me diate  safet y c o n cer ns t o t he 
s u bjects or w he n t he c ha n ge i n v ol ves o nl y n o ns u bsta ntial l o gistics or a d mi nistrati o n. T he 
i n vesti gat or, c o or di nati n g i n vesti gat or a n d t he s p o ns or will si g n t he pr ot oc ol a me n d me nt.  
1 1. 1. 2.  I m p ort a nt Pr ot oc ol De vi ati o ns  
A n y d e viati o n fr o m t he pr ot oc ol t hat affects, t o a si g nifica nt d e gree, (a) t he safet y, p h ysical, or 
me ntal i nte grit y of t he s u bjects i n t he st u d y a n d/ or ( b) t he scie ntific v al ue of t he st u d y will be 
c o nsi dere d a n i m p orta nt pr ot oc ol de viati o n. I m p orta nt pr ot oc ol de viati o ns ma y  i ncl u d e n o n -
a d here n ce o n t he p art of t he s u bject, t he i n vesti gat or, or t he s p o ns or t o pr ot oc ol -s pecific 
i ncl usi o n a n d e x cl usi o n criteria, pri mar y o bj ecti ve varia ble criteria, or G C P g ui deli nes; or 
n o nc o m plia nce t o I M P a d mi nistrati o n. I m p orta nt pr ot oc ol de viati o ns will be i de ntifie d a n d 
rec or de d b y st u d y staff o n a C R F a n d will be re p orte d t o t he res p o nsi ble I R B/I E C, as re q uire d.  
W he n a n i m p orta nt pr ot oc ol de viati o n is re p orte d, F HI [ADDRESS_1084007] 
safet y or sci e ntific val ue of t h e data, o n a Pr ot o c ol De viati o n L o g. T he c u m ulati ve l o g will be 
s u b mitte d t o t he res p o nsi ble I R B/I E C at a n n u al re vie ws, if/as re q uir e d.  
[ADDRESS_1084008] u d y's cli nical m o nit ori n g  pl a n w hic h is 
mai ntai ne d b y F HI [ADDRESS_1084009] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084010] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 5 8  f or m are warra nte d, i n acc or da nce wit h I R B/I E C a p pr o vals. T he st u d y m o nit or will be per mitte d 
t o c hec k a n d v erif y t he v ari o us rec or ds ( C R Fs a n d ot her perti ne nt s o urce data rec or ds), i ncl u di n g 
s pecific el ectr o nic s o ur ce d oc u me ntati o n (see Secti o n 1 3. 1 ) relati n g t o t he st u d y t o verif y 
a d here n ce t o t he pr ot oc ol a n d t o e ns ure t he c o m p lete ness, c o nsiste nc y, a n d acc urac y of t he data 
bei n g rec or de d.  
As part of t he s u per visi o n of st u d y pr o gress, ot her s p o ns or or F HI [ADDRESS_1084011] u d y m o nit or t o res ol ve a n y pr o ble ms, err ors, or 
p ossi ble mis u n dersta n di n gs c o n cer ni n g t he fi n di n gs detecte d d uri n g t hes e m o nit ori n g visits 
a n d/ or pr o vi de d i n f oll o w -u p writte n c o m m u nicati o n.  
[ADDRESS_1084012] ai nt is defi ne d as a pr o ble m or p ote ntial pr o ble m wit h t he p h ysical 
q ualit y or c h aracteristics of cli nical I M P s u p plies a n d/ or cli nical de vice s u p plies use d i n a 
s p o ns or’s cli nical res earc h st u d y. E x a m ples of a pr o d uct c o m plai nt i ncl u de b ut are n ot li mite d t o 
t he f oll o wi n g:  
• s us pecte d c o nta mi nati o n  
• q uesti o na ble sta bilit y (e g, c ol or c ha n ge, fla ki n g, cr u m bli n g, etc.)  
• defecti ve c o m p o ne nts  
• missi n g or e xtra u nits (e g, pri mar y c o ntai ner is recei ve d at t he i n vesti gati o n al ce nter 
wit h m ore or less t ha n t h e desi g n ate d n u m ber of u nits i nsi de)  
• i nc orrect pac k a gi n g or i nc orrect or missi n g la b eli n g/la bels  
• u ne x pecte d or u na ntici pate d taste or o d or, or b ot h  
• de vice n ot w or ki n g c orrectl y or a p pears defecti ve i n s o me ma n ner  
Eac h i n vesti gati o n al ce nt er will be res p o nsi ble f or re p orti n g a p ossi ble cli ni cal pr o d uct c o m plai nt 
b y c o m pleti n g t he Pr o d u ct C o m plai nt F or m pr o vi de d b y t h e s p o ns or a n d e maili n g it t o 
 wit hi n 4 8 h o urs of bec o mi n g a ware of t he iss ue.  
For c o m plai nts i n v ol vi n g a de vice or ot her retrie v a ble ite m, it is re q uire d t hat t he de vice ( or 
ite m) be se nt bac k t o t he s p o ns or f or i n vesti gati ve testi n g w he n e ver p ossi bl e. F or c o m plai nts 
i n v ol vi n g a n I M P, all rel e va nt sa m ples (e g, t h e re mai n der of t he s u bje ct’s I M P s u p pl y) s h o ul d be 
se nt bac k t o t he s p o ns or f or i n vesti gati ve t esti n g u p o n s p o ns or’s re q uest.  
[ADDRESS_1084013] C o m plai nt F or m ca n n ot be c o m plete d, t he i n v esti gat o r will o btai n 
t he f oll o wi n g i nf or m ati o n, as a vaila ble:  
• i n vesti gati o nal c e nter n u m ber a n d i n vesti gat or na me  
• na me, p h o ne n u m ber, a n d a d dress of t he s o urce of t he c o m plai nt  
• cli nical pr ot oc ol n u m ber  
V V- [ADDRESS_1084014] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084015] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 5 9  • s u bject i de ntifier (s u bject st u d y n u m ber) a n d c orres p o n di n g visit n u m bers, if 
a p plica ble  
• pr o d uct na me a n d stre n gt h f or o pe n la b el st u dies  
• s u bject n u m ber, b ottle, a n d kit n u m bers (if a p plica ble) f or d o u bl e -bli n d or o pe n la bel 
st u dies  
• pr o d uct a vaila ble f or ret ur n Yes/ N o  
• pr o d uct was ta k e n or use d i n acc or da nce wit h t h e pr ot oc ol Yes/ N o  
• descri pti o n or nat ur e of c o m plai nt  
• ass ociate d seri o us a d vers e e ve nt Y es/ N o  
• cli nical s u p plies u n bli n de d (f or bli n de d st u dies) Y es/ N o  
• date a n d na m e of pers o n recei vi n g t he c o m plai nt  
N ote: Re p orti n g a c o m pl ai nt m ust n ot be dela ye d e ve n if n ot all t he re q uire d i nf or mati o n ca n be 
i m me diatel y o btai ne d. K n o w n i nf or mati o n m ust be i m me diatel y re p orte d. T he s p o ns or will 
c olla b orate wit h t he i n vesti gat or t o o btai n a n y o utsta n di n g i nf or mati o n.  
[ADDRESS_1084016] c o m plai nt i n a 
l ocati o n se parate fr o m t h e i n vesti gat or’s cli nical st u d y s u p plies. T he s p o ns or ma y re q u est t hat t he 
i n vesti gat or ret ur n t he pr o d uct f or f urt h er e v al uati o n a n d/ or a nal ysis. If t his is necessar y, t h e 
cli nical st u d y m o nit or or desi g nee will pr o vi de t he i nf or mati o n nee de d f or ret ur ni n g t he I M P.  
If it is deter mi ne d t hat t he i n vesti gati o nal ce nter m ust ret ur n all I M P, t he s p o ns or will pr o vi de t he 
i nf or mati o n nee de d  t o h a n dle t he ret ur n.  
T he i nte grit y of t he ra n d o mizati o n c o de a n d c orres p o n di n g bli n de d cli nical s u p plies will be 
mai ntai ne d w he ne v er p ossi ble.  
[ADDRESS_1084017] y wit h 
i nter nati o nal re g ulat or y g ui deli nes, i ncl u di n g I nter nati o nal C o u ncil f or Har m o nisati o n ( I C H ) 
G C P g ui deli nes. Data m a na ge me nt a n d c o ntr ol pr ocesses s pecific t o t his st u d y, al o n g wit h all 
ste ps a n d a cti o ns ta ke n re gar di n g d ata ma n a ge me nt a n d data q ualit y c o ntr ol, will be descri be d i n 
a data ma n a ge me nt pla n.  
V V- [ADDRESS_1084018] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084019] a n d 
c o m plia nce wit h pr ot oc ols, S O Ps, G C Ps, a n d  a p plica ble re g ulat or y re q uire me nts. T he s p o ns or’s 
Gl o bal Cli nical Q ualit y Ass ura nce de part me nt, i n de pe n de nt of t he Gl o bal Cli nical De vel o p me nt 
de part me nt, is res p o nsi bl e f or det er mi ni n g t he n ee d f or (a n d ti mi n g of) a n i n vesti gati o nal c e nter 
a u dit.  
T he i n v esti gat or m ust acce pt t hat healt h a ut h orities a n d s p o ns or re prese ntati ves ma y c o n d uct 
i ns pecti o ns t o verif y c o m plia nce wit h G C P g ui deli nes.  
V V- [ADDRESS_1084020] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084021] u d y will be c o n d u cte d i n f ull acc or da nce wit h t he I C H Har m o nise d Tri par tite G ui deli ne 
f or G o o d Cli nical Practice ( G C P) E 6 a n d a n y a p plica ble nati o nal a n d l ocal la ws a n d re g ul ati o ns 
(e g, Title  2 1 C o de of Fe d eral Re g ulati o ns [ 2 1 C F R] Parts 1 1, 5 0, 5 4, 5 6, 3 1 2, a n d  3 1 4, Directi ve 
2 0 0 1/ 2 0/ E C of t he E u r o pea n Parlia me nt a n d of t he C o u ncil o n t he a p pr o xi mati o n of t he la ws, 
re g ulati o ns a n d a d mi nistrati ve pr o visi o ns of t he Me m ber States rel ati n g t o t he i m ple me ntati o n of 
G C P i n t he c o n d uct of cli nical st u dies o n me dici nal pr o d ucts f or h u ma n use). A n y e pis o de of 
n o nc o m plia nce will be d oc u me nte d.  
T he i n vesti gat or has t he o verall res p o nsi bilit y f or t he c o n d uct a n d a d mi nistrati o n of t he cli nical 
st u d y a n d f or c o nta cts wit h st u d y ma na ge m e nt, wit h t he I R B/I E C, a n d wit h healt h a ut h orities.  
T he i n vesti gat or is res p o nsi ble f or perf or mi n g t h e cli ni cal st u d y i n a cc or da nce wit h t his pr ot oc ol 
a n d t he a p plica ble G C P g ui deli nes refere n ce d a b o ve f or c ollecti n g, rec or di n g, a n d re p orti n g t he 
data acc urat el y a n d pr o p erl y. A gree me nt of t he i n vesti gat or t o c o n d uct a n d a d mi nister t his 
cli nical st u d y i n a cc or da n ce wit h t he pr ot oc ol will be d oc u me nte d i n se parate cli nical st u d y 
a gree m e nts wit h F HI [ADDRESS_1084022] u d y; a n d m ust e ns ure t hat trai ne d pers o n nel are i m me diatel y 
a vaila ble i n t he e v e nt of a me dical e mer ge n c y. T h e i n vesti gat or a n d t he i n v ol ve d cli nical st u d y 
pers o n nel m ust be f a mili ar wit h t he bac k gr o u n d a n d re q uire me nts of t h e st u d y; a n d wit h t he 
pr o perties of t he I M Ps as descri be d i n t he I B or prescri bi n g i nf or mati o n.  
T he i n vesti gat or is res p o nsi ble f or gi vi n g i nf or m ati o n a b o ut t he st u d y t o all staff me m bers 
i n v ol ve d i n t he st u d y or i n a n y ele me nt of s u bje ct ma na ge me nt, b ot h bef ore starti n g t he st u d y 
a n d d uri n g t he st u d y (e g, w he n ne w staff bec o me i n v ol ve d). T he i n vesti gat or m ust e ns ure t hat all 
st u d y pers o n n el are q ualifie d b y e d ucati o n, e x perie nce, a n d trai ni n g t o perf or m t he ir s pecific 
res p o nsi bilities. T hese st u d y pers o n nel m ust be liste d o n t he ce nter’s staff dele gati o n l o g, w hic h 
i ncl u des a cle ar des cri pti o n of eac h st aff me m b er’s res p o nsi bilities a n d a p pr o priatel y dele gate d 
si g nifica nt st u d y -relate d res p o nsi bilities. T his  list m ust be u p date d t hr o u g h o ut t he st u d y, as 
necessar y.  
1 2. 1.  He alt h A ut h orities a n d I n de pe n de nt Et hics C o m mittees/I nstit uti o n al 
Re vie w B o ar ds  
Bef ore t his st u d y starts, t he pr ot oc ol will be s u b mitte d t o healt h a ut h orities, if re q uire d, a n d t o 
eac h I R B/I E C f or re vie w. As re q uire d, t h e st u d y will n ot start at t he i n vesti gati o nal c e nters 
bef ore t h e I R B/I E C a n d healt h a ut h orit y (as a p pli ca ble) f or t he ce nter gi ve writte n a p pr o val or a 
fa v ora bl e o pi [INVESTIGATOR_9384] o n.  
[ADDRESS_1084023] u d y, i ncl u di n g t he writte n i nf or mati o n a p pr o ve d b y t he 
I R B/I E C. All writte n a n d oral i nf or mati o n a b o ut t he st u d y will be pr o vi d e d i n a la n g u a ge as 
V V- [ADDRESS_1084024] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084025] ’s willi n g ness t o p artici pate i n t he st u d y will be d oc u me nte d i n a n I C F, w hic h will be 
si g ne d a n d pers o n all y dat e d b y t h e s u bject a n d b y t he pers o n w h o c o n d ucte d t he i nf or me d 
c o nse nt disc ussi o n. T he i n vesti gat or will kee p t he ori gi nal c o ns e nt f or ms, a n d c o pi[INVESTIGATOR_787759] n t o t he s u bject. It will als o be e x plai ne d t o t he s u bject t hat t he s u bject is free t o r ef use e ntr y 
i nt o t he st u d y a n d free t o wit h dra w fr o m t he st u d y at a n y ti me wit h o ut prej u dice t o f ut ure 
treat me nt.  
[ADDRESS_1084026] e ns ure  t hat t he pri va c y of t he s u bjects, i ncl u di n g t h eir i de ntit y a n d all 
pers o nal me dic al i nf or mati o n, will be mai ntai ne d at all ti mes. I n C R Fs a n d ot her d oc u me nts or 
i ma ge m aterial s u b mitte d t o t he s p o ns or, s u bjects will be i de ntifie d n ot b y t h eir na mes, b ut b y a n 
i de ntificati o n c o de (ie, s u bject n u m ber).  
Pers o nal me dical i nf or m ati o n ma y b e re vie we d f or s u bject safet y a n d f or verif yi n g data i n t he 
s o urce a n d tr a nscri b e d o nt o t he C R F. T his re vie w ma y b e c o n d uct e d b y t he st u d y m o nit or, 
pr o perl y a u t h orize d pers o ns o n be half of t he s p o ns or or F HI 3 6 0, Gl o bal Q ualit y Ass ura nce 
( G Q A), or healt h a ut h orities. Pers o nal me dical i nf or mati o n will al wa ys b e treate d as 
c o nfi de ntial.  
[ADDRESS_1084027] u d y  
I n c o m plia nce wit h l ocal re g ulati o ns a n d i n acc or da nce wit h t he s p o ns or’s sta n dar d pr o ce d ures, 
t his cli nical st u d y will be re gistere d o n cli nicaltrials. g o v.  
V V- [ADDRESS_1084028] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084029] mai ntai n t he ori gi nal rec or ds (ie, s o urce d oc u me nts) of eac h 
s u bject’s dat a at all ti mes. T he i n vesti g at or will mai ntai n a c o nfi de ntial s u bject i de ntificati o n list 
t hat all o ws t he u na m bi g u o us i de ntificati o n of eac h s u bject. S u bject i de ntit y will n ot be 
discer ni ble fr o m t he d ata pr o vi de d o n C R Fs.  
E x a m ples of s o urce d oc u me nts are h os pi[INVESTIGATOR_21036], office vi sit rec or ds, e x a mi ni n g p h ysicia n’s 
fi n di n g or n otes, la b orat or y re p orts, dr u g i n v e nt or y, I M P la bel rec or ds, a n d w or ks heets t hat are 
use d as t he s o urce.  
S o me data ma y be rec or de d directl y o nt o t he C R F, if i nstr ucte d b y F HI 3 6 0; t he i n vesti gati o nal 
ce nter wi ll ge n erate a d o c u me nt s pecif yi n g w hic h data are rec or de d directl y o nt o C R Fs.  “ Cas e 
re p ort f or m ” mea ns a n y C R F, w het her p a per or el ectr o nic.  
T he me dical e x perts, st u d y m o nit ors, a u dit ors, I R B/I E C, a n d i ns pect ors fr o m healt h a ut h orities 
( or t heir a ge nts) wi ll be gi ve n direct a ccess t o s o ur ce data a n d d oc u me nts ( e g, me dical 
c harts/rec or ds, la b orat or y test res ults, pri nt o uts) f or s o urce d ata verificati o n, pr o vi de d t hat 
s u bject c o nfi de ntialit y is mai ntai ne d i n acc or da nce wit h nati o nal a n d l ocal r e q uire me nts.  
Al l data c ollecte d will be a p pr o ve d b y t he i n vesti gat or at t he i n vesti gati o nal ce nter. T his 
a p pr o val a c k n o wle d ges t he i n vesti gat or’s re vi e w a n d acce pta n ce of t he d at a as bei n g c o m plete 
a n d acc urate.  
T he data c ollecte d o n C R Fs will be e ntere d i n a C D M S t hat meets t he tec h nical re q uir e me nts 
descri be d i n 2 1 C F R  Part  1 1 ( U S A) a n d d oc u m e nts of ot her c o n cer ne d healt h a ut h orities. T he 
C D M S will be f ull y v ali date d t o e ns ure t h at it meets t he scie ntific, re g ulat or y, a n d l o gistical 
re q uire me nts of t h e st u d y bef ore it i s use d t o ca pt ure data fr o m t his st u d y. Bef ore usi n g t he 
C D M S, all users will recei ve trai ni n g o n t he s yste m a n d st u d y s pecific trai ni n g. Aft er t he y are 
trai ne d, users will be pr o vi de d wit h i n di vi d ual s yste m access ri g hts.  
F or s u bjects w h o si g n a n I C F b ut d o n ot meet eli gi bilit y criteria, at a mi ni m u m, data f or scree n 
fail ure reas o n, de m o gra p h y, a n d a d vers e e v e nts fr o m t he ti me of i nf or me d c o nse nt will be 
e ntere d o nt o a C R F.  
[ADDRESS_1084030] u d y a n d a n y a d diti o nal rec or ds re q uire d t o be mai ntai n e d u n der c o u ntr y, 
state/ pr o vi nce, or nati o nal a n d l ocal la ws, i ncl u di n g, b ut n ot li mite d t o:  
V V- [ADDRESS_1084031] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084032] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 6 4  • f ull case hist ories  
• si g ne d I C Fs  
• s u bject i de ntificati o n lists  
• case re p ort f or ms f or eac h s u bject o n a per -visit basis  
• data fr o m ot her s o urces (e g, e xter nal la b orat or y)  
• safet y re p orts  
• re p orts of recei pt, use, a n d dis p ositi o n of t he I M Ps  
• c o pi[INVESTIGATOR_3951] c orres p o n de nce wit h F HI 3 6 0, t he I R B/I E C, a n d a n y h ealt h a ut h orit y  
T he i n ves ti gat or will retai n all rec or ds relate d t o t he st u d y a n d a n y a d diti o nal rec or ds re q uir e d, as 
i n dicate d b y t he pr ot oc ol a n d acc or di n g t o a p plica ble la ws a n d re g ulati o ns, u ntil F HI [ADDRESS_1084033] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084034] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084035] u d y i n acc or da nce wit h t he c urre nt “ Rec o m me n dati o ns  f or t he C o n d uct, 
Re p orti n g, E diti n g, a n d P u blicati o n of Sc h olarl y W or k i n Me d ical J o ur nals” ( w w w.I C MJ E. or g). 
P u blicati o n of t he res ults will occ ur i n a ti mel y m a n ner acc or di n g t o a p plic a ble re g ulati o ns. 
A ut h ors hi p will be base d o n meeti n g all t he f oll o wi n g 4  criteria:  
• s u bsta ntial c o ntri b uti o ns t o t he c o nce pti o n or desi g n of t he w or k; or t he ac q uisiti o n, 
a nal ysis, or i nter pret ati o n of data f or t h e w or k  
• drafti n g t he w or k or re visi n g it criticall y f or i m p ort a nt i ntellect ual c o nte nt  
• fi nal a p pr o val of t h e versi o n t o be p u blis he d  
• a gree m e nt t o be acc o u nta ble f or all as pects of t he w or k i n e ns uri n g t hat q uesti o ns 
relate d t o t he acc urac y or i nte grit y of a n y part of t he w or k are a p pr o priatel y 
i n vesti gate d a n d res ol ve d.  
A j oi nt p u blicati o ns c o m mittee will be esta blis he d b y t he s p o ns or a n d F HI  [ADDRESS_1084036] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084037] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 6 7  1 6.  R E F E R E N C E S  
C o m mittee o n Practice B ulleti ns G y nec ol o g y. Practice B ulleti n N o. 1 6 8: C er vical Ca n cer 
Scree ni n g a n d Pre ve nti o n. O bstet G y n ec ol 2 0 1 6; 1 2 8( 4):e 1 1 1 -3 0.  
De p o -Pr o vera C o ntrace pti ve I nje cti o n U S prescri bi n g i nf or mati o n. N e w Y or k, N Y: [COMPANY_007] I nc ; 
[ADDRESS_1084038] o x y pr o gester o ne acetate i njecti o n, sterile a q ue o us s us pe nsi o n U S prescri bi n g 
i nf or mati o n. Ne w Y or k, N Y: [COMPANY_007] I n c; 2 0 1 7.  
De p o -s u b Q Pr o vera 1 0 4 U S prescri bi n g i nf or mati o n. Ne w Y or k, N Y: [COMPANY_007] I nc; 2 0 1 6.  
J ai n J, D utt o n C, Nic osia A , Wajsz cz u k C, B o de F R, Mis hell D R Jr. P har mac o ki netics, o v ulati o n 
s u p pressi o n a n d ret ur n t o o v ulati o n f oll o wi n g a l o wer d ose s u b c uta ne o us f or m ulati o n of De p o -
Pr o vera. C o ntrace pti o n. 2 0 0 4; 7 0( 1): 1 1 -8.  
Kr oe n ke K, S pi[INVESTIGATOR_260585] R L, Willia ms J B. T he P H Q -9: vali dit y of a bri ef de pressi o n se verit y 
meas ure. J Ge n I nter n Me d  2 0 0 1; 1 6( 9): [ADDRESS_1084039] o x y pr o gester o ne acetate ( 1 0 4  m g/ 0. 6 5  m L) c o ntrace pti ve f or m ulati o n i n Asia n 
w o m e n. Cli nical T hera p e utics. 2 0 0 4; 2 6( 1 1): [ADDRESS_1084040] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084041] or y d uri n g t he scree ni n g p h ase . 
A ta ble s h o wi n g t he c ha n ges fr o m t he Pr ot oc ol wit h A me n d me nt 0 1 t o A me n d me nt 0 2 is 
pr o vi de d bel o w. All maj or c ha n ges t o t he pr ot oc ol b o d y are liste d bel o w i n t he ta ble, a n d are 
reflecte d i n t he s y n o psis, as a p plica ble. P re vi o us te xt wit h c ha n ges i n dicate d is prese nte d i n t he 
c ol u m n title d " Ori gi nal te xt wit h c ha n ges s h o w n", a n d t he fi nal te xt is prese nte d i n t he c ol u m n 
title d " Ne w w or di n g." A d de d te xt is s h o w n i n u n derli ne a n d del eti o ns are s h o w n i n stri ke -
t hr o u g h.  
Ta ble 1 ( St u d y Pr oce d ures a n d Assess me nts) h as bee n re vis e d t o refl ect c h a n ges descri be d 
bel o w.  
Mi n or e dit orial c ha n ges (t y p os, p u nct uati o n, r e pla ci n g te xt wit h a b bre viati o ns, etc) ha v e bee n 
ma de t o t he pr ot oc ol a n d pr ot oc ol s y n o psis, as a p pr o priate.  
Ori gi n al te xt wit h c h a n ges s h o w n  Ne w w or di n g  Re as o n/ J ustific ati o n f or 
c h a n ge  
Secti o n 1. 3. [ADDRESS_1084042] of a 
scree ni n g peri o d ( u p t o  a p pr o xi matel y  1. 5 
m o nt hs, or 6 wee ks),  St u d y partici pati o n will c o nsist of a 
scree ni n g peri o d ( a p pr o xi mat el y 1. 5 
m o nt hs, or 6 wee ks),  U p date. Descri pti o n of 
scree ni n g p hase peri o d 
u p date d  
Secti o n 2. [ADDRESS_1084043] u d y O bjecti ves a n d M e as ures/ P ar a meters  
V V- [ADDRESS_1084044] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084045] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 6 9  Ori gi n al te xt wit h c h a n ges s h o w n  Ne w w or di n g  Re as o n/ J ustific ati o n f or 
c h a n ge  
T he safet y a n d l ocal t olera bilit y  
meas ures/ para meters are : 
• c ha n ge i n  vital si g ns ( bl o o d press ure, 
res pi[INVESTIGATOR_1305] y rate, b o d y te m perat ure, 
a n d p ulse) a n d b o d y wei g ht 
meas ure me nt  
• c ha n ge i n b o d y wei g ht  
• c ha n ge i n  va gi nal blee di n g patter n  
• c ha n ge i n m o o d assess me nt of m o o d 
b y P atie nt Healt h Q uesti o n naire -9 
( P H Q -9)  
• c ha n ge i n  li ver f u ncti o n tests  
• c ha n ge i n estra di ol ( E 2) le vels  
meas ure me nts t hr o u g h o ut t he st u d y  
• dela ye d ret ur n t o o v ulati o n ( > 1 2 
m o nt hs after treat me nt i nitiati o n) 
w here o v ulati o n is defi ne d as a si n gle 
P ≥ 4. 7 n g/ m L pr o gester o ne ( P) 
meas ure me nts at W ee ks 4 8, 4 9, 5 0 , 
5 1, a n d 5 2  T he safet y a n d l ocal t olera bilit y  
meas ures/ para meters are : 
• vital si g ns a n d b o d y wei g ht 
meas ure me nt  
• va gi nal blee di n g patter n  
• assess me nt of m o o d b y P atie nt 
Healt h Q uesti o n naire -9 ( P H Q -9)  
• li ver f u ncti o n tests  
• estra di ol ( E 2) meas ure me nts 
t hr o u g h o u t t he st u d y  
• pr o gester o ne ( P) meas ure me nts at 
W ee ks 4 8, 4 9, 5 0, 5 1, a n d 5 2  U p date. Defi niti o n of t he 
safet y a n d l ocal t olera bilit y  
meas ures/ para meters 
u p date d . 
 
Secti o n 3. [ADDRESS_1084046] u d y Pr o ce d ures a n d Assess me nts  
See Ne w w or di n g c ol u m n  T a ble 1 ( St u d y Pr oce d ures a n d 
Assess me nts) has bee n re vise d as descri be d 
bel o w:  
• Me dical hist or y re m o ve d fr o m  
e nr oll me nt p hase  da y 0) i n T a ble 
1 
• De m o gra p hics, c o ntrace pti ve a n d 
re pr o d ucti ve hist or y re m o ve d 
fr o m enr oll me nt p hase ( Da y 0)  i n 
T a ble 1  
• M o o d eval uati o n re m o ve d fr o m  
scree ni n g p hase  ( 6 wee ks bef ore 
Ra n d o mizati o n)  i n T a ble 1  
• Va gi nal blee di n g patter n 
re m o ve d fr o m  scree ni n g p has e  ( [ADDRESS_1084047] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084048] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 7 0  Ori gi n al te xt wit h c h a n ges s h o w n  Ne w w or di n g  Re as o n/ J ustific ati o n f or 
c h a n ge  
wee ks bef ore Ra n d o mizati o n) 
a n d la b visits ( F oll o w -U p)  i n 
T a bl e [ADDRESS_1084049] or y , meas ure me nt of 
he m o gl o bi n a n d li ver e nz y mes, a n d 
p h ysical e xa mi nati o n t hat will i ncl u de, at 
mi ni m u m: hea d/ nec k, ears, e yes, n ose, 
t hr oat, c hest a n d l u n gs, car di o vasc ular, 
a b d o me n, s ki n, l y m p h n o des a n d breast 
assess me nts.  De m o gra p hic data a s well as c o ntrace pti ve 
a n d re pr o d ucti ve hist or y will be c ollecte d 
a n d d oc u me nte d. Scree ni n g f or eli gi bilit y, 
will i ncl u de  re vie w of eli gi bilit y criteria 
a n d me dical hist or y,  meas ure me nt of 
he m o gl o bi n a n d li ver e nz y mes, a n d 
p h ysical e xa mi nati o n t hat will i ncl u de, at 
mi ni m u m: hea d/ nec k, ears, e yes, n ose, 
t hr oat, c hest a n d l u n gs, car di o vasc ular, 
a b d o me n, s ki n, l y m p h n o des a n d breast 
assess me nts.  A d diti o n a n d u p date. 
Re q uire me nt f or 
de m o gra p hic data a n d 
c o ntrace pti ve a n d 
re pr o d ucti ve hist or y 
c ollecti o n was a d d e d t o 
scree ni n g p hase .  
Scree ni n g f or e li gi bilit y 
u p date d.  
B MI will be calc ulate d base d o n t he 
meas ure d wei g ht a n d hei g ht.   
 
 
 
 
 
 
 
 B MI will be calc ulate d base d o n t he 
meas ure d wei g ht a n d hei g ht.   
 
 
 
 
 
 
 
 A d diti o n.  
  
 
 
 
Secti o n 3. 4. 2. Pr o ce d ures f or E nr oll me nt  ( D a y 0)  
Secti o n 3. 4. 2. Pr o ce d ures f or Tre at me nt 
I niti ati o n  E nr oll me nt  ( D a y 0)  Secti o n 3. 4. 2. Pr o ce d ures f or E nr oll me nt 
( D a y 0)  Title of Secti o n 3. 4. [ADDRESS_1084050] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084051] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 7 1  Ori gi n al te xt wit h c h a n ges s h o w n  Ne w w or di n g  Re as o n/ J ustific ati o n f or 
c h a n ge  
T he i nj ecti o n site l ocati o n will be mar ke d 
a n d p h ot o gra p he d f or refere nc e.  
 
 
 
 T he 
i nj ecti o n site will be o bser ve d f or i nj ecti o n 
site reacti o ns (I S Rs) i m me diat el y (ie, as 
s o o n as p ossi ble b ut n o later t ha n 1 0 
mi n utes u p o n re m o vi n g t he n e e dle) a n d 1 
h o ur ( ± 5 mi n utes) after t he i nj ecti o n . T he i nj ecti o n site l ocati o n will be mar ke d 
a n d p h ot o gra p he d f or refere nc e. T he 
i nj ecti o n site will be o bser ve d f or i nj ecti o n 
site reacti o ns (I S Rs) i m me diat el y  (ie, as 
s o o n as p ossi ble b ut n o later t ha n 1 0  
mi n utes u p o n re m o vi n g t he ne e dle) a n d 1 
h o ur ( ± 5 mi n utes) after t he i nj ecti o n . Deleti o n.  
 
 
 
Secti o n 5. [ADDRESS_1084052] e d i n  
T a ble  1: 
• i nci de nce  occ urre nce  of a d verse 
e ve nts  
• use of  c o nc o mita nt me dicati o n use  
• c ha n ge i n b o d y wei g ht  
• assess me nt of  va gi nal blee di n g 
patter n  
• assess me nt of m o o d  b y P atie nt 
Healt h Q uesti o n naire -9 ( P H Q -9)  
• E [ADDRESS_1084053] u d y  
• assess me nt of ret ur n t o o v ulati o n at 
5 2 wee ks as meas ure d b y P 
meas ure me nts at W ee ks 4 8, 4 9, 5 0, 
5 1, a n d 5 2  
• i nci de nce  occ urre nce  of i nj ecti o n site 
reacti o ns ( I S Rs ) T he f oll o wi n g safet y a n d l ocal t olera bilit y 
meas ures will b e i m ple me nte d t hr o u g h o ut 
t he st u d y at t he ti me p oi nts list e d i n  
T a ble  1: 
• occ urre nce of a d verse e ve nts  
• use of c o nc o mita nt me dicati o n  
• va gi nal blee di n g patter n  
• assess me nt of m o o d b y P atie nt 
Hea lt h Q uesti o n naire -9 ( P H Q -9)  
• E [ADDRESS_1084054] u d y  
• P meas ure me nts at W ee ks 4 8, 4 9, 5 0, 
5 1, a n d 5 2  
• occ urre nce of i nj ecti o n site reacti o ns 
(I S Rs ) U p date. Defi niti o n of t he 
safet y a n d l ocal t olera bilit y  
meas ures u p date d . 
 
Secti o n 5. 1. [ADDRESS_1084055] u d y ( T a ble 1 ).  S u bj ects will be i nter vie we d a b o ut as pects 
of a n d c ha n ges i n m o o d at e nr oll me nt a n d 
at pre -defi ne d  ti me p oi nts t hr o u g h o ut t he 
st u d y ( T a ble 1 ).  U p date. Ti mi n g of s u bj ects’ 
i nter vie w o n m o o d c ha n ges 
u p date d  
Secti o n 5. 2. 1 Defi niti o n of a n A d verse E ve nt  
• F or t he p ur p ose of t his st u d y, irre g ular 
va gi nal blee di n g will n ot b e c o nsi dere d a n 
a d verse e ve nt u nless it re q uires me dical 
i nter ve nti o n or meets t he defi niti o n of 
“seri o us a d verse e ve nt ” ( See S ecti o n 5. 2. 5 ) • F or t he p ur p ose of t his st u d y, irre g ular 
va gi nal blee di n g will n ot b e c o nsi dere d a n 
a d verse e ve nt u nless it re q uires me dical 
i nter ve nti o n or m eets t he defi niti o n of 
“seri o us a d verse e ve nt”  ( See S ecti o n 5. 2. 5 )  A d diti o n. Clarificati o n o n 
irre g ular va gi nal blee di n g as 
a n a d verse e ve nt a d de d.  
Secti o n 9. [ADDRESS_1084056] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084057] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 7 2  Ori gi n al te xt wit h c h a n ges s h o w n  Ne w w or di n g  Re as o n/ J ustific ati o n f or 
c h a n ge  
T he i nte nt of t he st u d y is t o ha ve a 
mi ni m u m of [ADDRESS_1084058]’s 
c h ar a cteristics re q uire d  
f or assess me nt of 
tre at me nt c o m p ar a bilit y  
u p d ate d  
Secti o n 9. [ADDRESS_1084059] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084060] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 7 3  Ori gi n al te xt wit h c h a n ges s h o w n  Ne w w or di n g  Re as o n/ J ustific ati o n f or 
c h a n ge  
Safet y a n d l ocal t olera bilit y e val uati o n will 
be base d o n t he f oll o wi n g:  
• occ urre nce  i nci de nce  of 
a d verse e ve nts  
• use of  c o nc o mita nt 
me dicati o n use  
• c ha n ge i n  vital si g ns a n d 
b o d y wei g ht meas ure me nt  
• c ha n ge i n  assess me nt of  
m o o d  
• c ha n ge i n  li ver f u ncti o n tests  
• c ha n ge i n  E 2 le vels 
c o nce ntrati o n meas ure me nt   
• dela ye d  assess me nt of  ret ur n 
t o o v ulati o n ( > 1 2 m o nt hs 
after treat me nt i nitiati o n) 
w here o v u lati o n is defi ne d as 
a si n gle P ≥ 4. 7 n g/ m L  at 5 2 
wee ks as meas ure d b y 
P ≥ 4. 7 n g/ m L  
• occ urre nce of  i nci de nce of 
I S Rs  Safet y a n d l oca l t olera bilit y e val uati o n 
will b e base d o n t he f oll o wi n g:  
• occ urre nce of a d verse e ve nts  
• use of c o nc o mita nt 
me dicati o n  
• c ha n ge i n vital si g ns a n d 
b o d y wei g ht  
• c ha n ge i n m o o d  
• c ha n ge i n li ver f u ncti o n tests  
• E 2 le vels  
• dela ye d ret ur n t o o v ulati o n 
( > 1 2 m o nt hs af ter treat me nt 
i nitiati o n) w here o v u lati o n is 
defi ne d as a si n gle P ≥ 4. 7 
n g/ m L  
• occ urre nce of I S Rs  
 U p date. Clarificati o n o n 
defi niti o n of safet y a n d 
l ocal t olera bilit y e val uati o n 
meas ure me nts.  
Seri o us a d verse e ve nts a n d a d verse e ve nts 
lea di n g t o wit h dra wal fr o m t he st u d y will 
be liste d se p aratel y. C o nc o mit a nt 
me dicati o n use will be s u m marize d b y 
treat me nt gr o u p i n fre q ue nc y t a bles, b y 
t hera p e utic class a n d me dici ne cate g or y . Seri o us a d verse e ve n ts a n d a d verse e ve nts 
lea di n g t o wit h dra wal fr o m t he st u d y will 
be liste d se p aratel y. C o nc o mit a nt 
me dicati o n use will be s u m marize d b y 
treat me nt gr o u p i n fre q ue nc y t a bles, b y 
t hera p e utic class a n d me dici ne cate g or y.  A d diti o n. Clarificati o n o n 
s u m maries cla ssificati o n of 
c o nc o mita nt me dicati o n use 
a d de d.  
M o o d data will be s u m marize d o ver ti me 
fr o m  i n ta bles at  Da y [ADDRESS_1084061] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084062] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 7 4  Ori gi n al te xt wit h c h a n ges s h o w n  Ne w w or di n g  Re as o n/ J ustific ati o n f or 
c h a n ge  
I nstit uti o n al Re vie w B o ar ds  
Mi dla n ds  W C G  I R B  
1 0 1 9 3 9t h A ve., S E  
S uite 1 2 0  
P u yall u p, W A 9 8 3 7 4  
8 2 0 7 Melr ose Dri ve, S uite 2 0 5  
Le ne xa, Ka nsas 6 6 2 1 4  
U nite d States of A merica  I nstit uti o n al Re vie w B o ar ds  
W C G I R B  
1 0 1 9 3 9t h A ve., S E  
S uite 1 2 0  
P u yall u p, W A 9 8 3 7 4  
U nite d States of A merica  U p date d a d dress  
A p pe n di x B S P E CI M E N S A M P LI N G A N D H A N D LI N G  
Sa m ple pr ocessi n g (ser u m):  
1. C ollect sa m ples (a p pr o xi matel y 5 m L) 
i nt o Vac utai ner ® t u bes (t u be r e d t o p, 1 3 x 
7 5 m m, silic o ne c o ate d i nteri or)  c o ntai ni n g 
n o a ntic oa g ula nt  
2. I m me diatel y after t he sa m pl e is dra w n, 
ge ntl y i n vert t he t u be [ADDRESS_1084063] 2 0  mi n utes ( n o m ore t ha n 4 0 
mi n utes)  
3. Ce ntrif u ge ~ 1 0 -1 5  mi n utes ( at r o o m 
te m perat ure at 2 5 0 0 t o 3 0 0 0 r p m 
[a p pr o xi matel y 6 5 0 t o 1 4 5 0 x g ] 4°C t o 
8°C, 2 0 0 0 g ) t o ac hie ve a clear ser u m la yer 
o ver t he cl otte d re d cells (t he s pee d a n d 
ti me ma y be varie d acc or di n g t o t he ma ke 
a n d m o del of ce ntrif u ge use d)  Sa m ple pr ocessi n g (ser u m):  
1. C ollect sa m ples (a p pr o xi matel y 5 m L) 
i nt o Vac utai ner ® t u bes (t u be r e d t o p, 1 3 x 
7 5 m m, silic o ne c o ate d i nteri or) c o ntai ni n g 
n o a ntic oa g ula nt  
2. I m me diatel y after t he sa m pl e is dra w n, 
ge ntl y i n vert t he t u be [ADDRESS_1084064] 2 0 
mi n utes ( n o m ore t ha n 4 0 mi n utes)  
3. Ce ntrif u ge ~ 1 0 -1 5 mi n utes (at r o o m 
te m perat ure at 2 5 0 0 t o 3 0 0 0 r p m 
[a p pr o xi matel y 6 5 0 t o 1 4 5 0 x g]) t o 
ac hie ve a clear ser u m la yer o ver t he cl otte d 
re d cells (t he s pee d a n d ti me ma y be varie d 
acc or di n g t o t he ma ke a n d m o del of 
ce ntrif u ge use d)  A d diti o n a n d u p date. 
I nf or mati o n a d de d o n t y pe 
of sa m ple t u be, t u be 
ha n dli n g a n d ce ntrif u ge.  
St ora g e:  
Sa m ples will be st ore d at a te m perat ure of 
–270° C i n a n u pri g ht p ositi o n u ntil t he y are 
s hi p pe d t o t he bi oa nal ytical la b orat or y.  St ora ge:  
Sa m ples will be st ore d at a te m perat ure of 
–2 0° C i n a n u pri g ht p ositi o n u ntil t he y are 
s hi p pe d t o t he bi oa nal ytical  la b orat or y.  U p date. St ora ge te m perat ure 
of ser u m sa m ple u p date d  
St ora ge:  
F or e ver y M P A bl o o d dra w, b atc h o ne 
ali q u ot (“ali q u ot 1 ”) f or e ve nt ual s hi p me nt 
t o P P D st ore, a n d o ne ali q u ot (“ali q u ot 2 ”) 
t o be st ore d o n site d uri n g t he st u d y as bac k 
u p i n case a d diti o nal testi n g is nee de d . 
St ora ge at 1 5° C t o 2 5° C wit h o ut a n y 
freeze/t ha w is acce pta ble f or a peri o d of u p 
t o 4 da ys if a freezer wit h a te m perat ure of 
≤6 5° C is n ot a vaila ble.  St ora ge:  
F or e ver y M P A bl o o d dra w, b atc h o ne 
ali q u ot (“ali q u ot 1 ”) f or e v e nt ual s hi p me nt 
t o P P D st ore, a n d o ne ali q u ot (“ali q u ot 2 ”) 
t o be st ore d o n site d uri n g t he st u d y as 
bac k u p i n case a d diti o nal testi n g is 
nee de d.  U p date. State me nt o n 
sa m ple ali q u ots a d de d a n d 
i nf or mati o n o n acce pta ble 
peri o d of freeze/t ha w 
re m o ve d.  
 
V V- [ADDRESS_1084065] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084066] u d y.  
A ta ble s h o wi n g t he c ha n ges fr o m t he Pr ot oc ol t o A me n d me nt 0 1 is pr o vi de d bel o w. All maj or 
c ha n ges t o t he pr ot o c ol b o d y are liste d bel o w i n t h e ta ble, a n d are reflecte d i n t he s y n o psis, as 
a p plica ble. Pre vi o us te xt wit h c ha n ges i n dicate d is prese nte d i n t h e c ol u m n title d " Ori gi nal te xt 
wit h c ha n ges s h o w n", a n d t he fi nal te xt is prese nte d i n t he c ol u m n title d " Ne w w or di n g." A d d e d 
te xt is s h o w n i n u n derli ne a n d deleti o ns are s h o w n i n stri ke -t hr o u g h.  
T he Sc he d ule of Pr oce d ures a n d Assess me nts ta bl e ( Ta ble 1) has bee n re vise d t o reflect t he 
c ha n ges des cri be d b el o w as a p plica ble. Listi n gs of i n di vi d ual c ollecti o n or assess me nt ti mes 
ha ve bee n re pla ce d wit h a refere n ce t o T a ble 1. O nl y t he title of a n a d diti o nal ta ble a d de d t o t he 
b o d y of t h e pr ot oc ol has bee n i n cl u de d i n t he s u m mar y of c h a n ges.  
Mi n or e dit orial c ha n ges (t y p os, p u nct uati o n, r e pla ci n g te xt wit h a b bre viati o ns, etc) ha v e bee n 
ma de t o t he pr ot oc ol a n d pr ot oc ol s y n o psis, as a p pr o priate.  
Ori gi n al te xt wit h c h a n ges s h o w n  Ne w w or di n g  Re as o n/ J ustific ati o n f or 
c h a n ge  
Secti o n 1. 4. 1.  Ge ner al St u d y Desi g n R ati o n ale  
St u d y partici pati o n will c o nsist of a 
scree ni n g peri o d ( u p t o 1. 5 m o nt hs, or 6 
wee ks), treat me nt i nitiati o n ( D a y 0), a n d at 
least  [ADDRESS_1084067] of a 
scree ni n g peri o d ( u p t o 1. 5 m o nt hs, or 6 
wee ks), treat me nt i nitiati o n ( D a y 0), a n d at 
least [ADDRESS_1084068] u d y d urati o n 
e xte n de d.  
S u bj ects wit h u nres ol ve d I S R(s) at W ee k 5 2 
will b e f oll o we d e ver y 3 m o nt hs t hr o u g h t he 
res ol uti o n of I S R(s) or W ee k [ADDRESS_1084069].  S u bj ects wit h u nres ol ve d I S R(s) at W ee k 
5 2 will be f oll o we d e ver y 3 m o nt hs 
t hr o u g h t he res ol uti o n of I S R(s) or W ee k 
[ADDRESS_1084070] u d y d urati o n 
e xte n de d.  
After treat me nt i nitiati o n , s u bj ects will be  
f oll o we d f or 5 2 wee ks a n d pr o vi de bl o o d 
sa m ples f or M P A at t he f oll o wi n g ti me 
p oi nts: Da ys 0, 1, 2, 3, 5, 7, 1 0, 1 2, 1 4, 1 8, 
2 1, a n d 2 8; W ee ks 6, 8, 1 0, 1 2, 1 3, 1 5, 1 7, 
1 9, 2 1, 2 3, 2 5, 2 6, 2 8, 3 0, a n d 3 2; a n d t he n 
e ver y 2 8 da ys t hr o u g h W ee k 5 2. Bl o o d 
sa m p les f or pr o gester o ne,  (P,) will b e 
c ollecte d at W ee ks 4 8, 4 9, 5 0, 5 1 a n d 5 2. I n 
a d diti o n, starti n g o n Da y 2 8 bl o o d sa m ples 
f or a n d  estra di ol ( E 2) as s h o w n i n T a ble 
1. will be c ollecte d e ver y ti me M P A or P is 
meas ure d.  After treat me nt i nitiati o n, s u bj ects wi ll be 
f oll o we d f or 5 2  wee ks a n d pr o vi de bl o o d 
sa m ples f or M P A, P, a n d estra di ol  ( E 2) as 
s h o w n i n T a ble 1.  U p date. Ti me p oi nts 
re m o ve d a n d refere nce 
ma d e t o T a ble 1.  
Va gi nal blee di n g patter n, acce pta bilit y, a n d 
m o o d will be assesse d t hr o u g h o ut t he st u d y 
at pre d efi ne d ti me p oi nts . a n d acce pta bilit y 
will b e assesse d at W ee ks [ADDRESS_1084071] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084072] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 7 6  Ori gi n al te xt wit h c h a n ges s h o w n  Ne w w or di n g  Re as o n/ J ustific ati o n f or 
c h a n ge  
Uri ne pre g na nc y test will be perf or me d 
e ver y [ADDRESS_1084073] u d y Desi g n ( Fi g ure 1)  
F oll o w -u p ( 1 2 m o nt hs  u p t o 1 8 m o nt hs ) F oll o w -u p ( u p t o 1 8 m o nt hs)  U p date. D urati o n of st u d y 
e xte n de d.  
Secti o n 3. 2. 2.  S u bject E xcl usi o n Criteri a  
aa.  has k n o w n se nsiti vit y t o M P A or 
i nacti ve i n gre die nts  
b b. has s ki n dis or ders or s ki n aller gies 
w hic h i n t he o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or 
w o ul d ma ke st u d y partici pati o n u nsafe or 
c o m plicate data i nter pretati o n  
cc. pla ns t o m o ve t o a n ot her l ocati o n i n t he 
ne xt [ADDRESS_1084074] 5 2 wee ks after 
treat me nt i nitiati o n.  If s u bj ects ha ve 
u nres ol ve d I S R(s) at W ee k [ADDRESS_1084075] 5 2 
wee ks after treat me nt i n itiati o n.  If s u bj ects 
ha ve u nres ol ve d I S R(s) at W ee k [ADDRESS_1084076] u d y Pr o ce d ures ( T a ble 1)  
a S u bj ects will ret ur n f or la b orat or y visits at 
pre -defi ne d ti me p oi nts: Da ys 0, 1, 2, 3, 5, 
7, 1 0, 1 2, 1 4, 1 8, 2 1, a n d 2 8; W ee ks 6, 8, 
1 0, 1 2, 1 3, 1 5, 1 7, 1 9, 2 1, 2 3, 2 5, 2 6, 2 8, 
3 0, a n d 3 2; a n d t he n e ver y 2 8 da ys t hr o u g h 
W ee k 5 2.  a S u bj ects will ret ur n f o r la b orat or y visits 
at pre -defi ne d ti me p oi nts: Da ys 0, 1, 2, 3, 
5, 7, 1 0, 1 2, 1 4, 1 8, 2 1, a n d 2 8; W ee ks 6, 
8, 1 0, 1 2, 1 3, 1 5, 1 7, 1 9, 2 1, 2 3, 2 5, 2 6, 
2 8, 3 0, a n d 3 2; a n d t he n e ver y [ADDRESS_1084077] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084078] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 7 7  Ori gi n al te xt wit h c h a n ges s h o w n  Ne w w or di n g  Re as o n/ J ustific ati o n f or 
c h a n ge  
a b A uri ne pre g na nc y test will be perf or me d 
o n Da y 0; W ee ks 2 6, 3 2, 3 6, 4 0, 4 4, 4 8, a n d 
5 2; a n d at W ee ks [ADDRESS_1084079] will be perf or me d at 
Da y 0; e ver y [ADDRESS_1084080] will be 
perf or me d o n Da y 0; W ee ks 2 6, 3 2, 3 6, 
4 0, 4 4, 4 8, a n d 5 2; a n d at W ee ks 6 5 a n d 
7 8 if a p plica ble, a n d at a n y ot her ti mes 
w he n i n dicate d.  U p date. F o ot n ote descri bi n g 
ti mi n g of pre g na nc y tests 
u p date d.  
edI S Rs will be e val uate d o n D a y 0  
i m me diatel y (ie, as s o o n as p ossi ble b ut n o 
later t ha n 1 0 mi n utes u p o n re m o vi n g t he 
nee dle) a n d 1 h o ur ( ± 5 mi n utes) after 
i nj ecti o n ; Da y 7; at W ee ks 1 3, 2 6, a n d 5 2 
a n d at ot her visits, if i n dicate d. S u bj ects 
w h o ha ve I S R(s) at W ee k 5 2 will b e 
f oll o we d e ver y 3 m o nt hs (at W ee ks 6 5 a n d 
7 8) u ntil I S R res ol uti o n or W ee k [ADDRESS_1084081] d oes n ot 
ha ve a n y I S Rs at W ee k 5 2 it will b e her 
fi nal visit. All s u bj ects will be i nstr ucte d t o 
ret ur n t o t he cli nic if a n y I S Rs de vel o p after 
t heir fi nal visit.  eI S Rs will b e e val uate d o n Da y 0  
i m me diatel y (ie, as s o o n as p ossi ble b ut 
n o later t ha n 1 0 mi n utes u p o n re m o vi n g 
t he nee dle) a n d 1 h o ur ( ± 5 mi n utes) after 
i nj ecti o n ; Da y 7; at W ee ks 1 3, 2 6, a n d 5 2 
a n d at ot her visits, if i n dicate d. S u bj ects 
w h o ha ve I S R(s) at W ee k 5 2 will b e 
f oll o we d e ver y 3 m o nt hs (at W ee ks 6 5 
a n d 7 8) u ntil I S R res ol uti o n or W ee k [ADDRESS_1084082]. A d verse e ve nts a n d use of 
c o nc o mita nt me dicati o ns will als o be 
e val uate d d uri n g a d diti o nal I S R f oll o w u p 
at W ee ks 6 5 a n d 7 8.  U p date. F o ot n ote descri bi n g 
t he d oc u me ntati o n of 
a d verse e ve nts a n d 
c o nc o mita nt me dicati o ns 
d uri n g t he f oll o w -u p peri o d 
u p date d.  
hgM o o d will be e val uate d o n Da ys 0 a n d 2 8; 
W ee ks 8, [ADDRESS_1084083] u d y.  hM o o d will be e val uate d o n Da ys 0 a n d 
2 8; W ee ks 8, [ADDRESS_1084084] u d y at pre -defi ne d ti me p oi nts ( See 
T a ble 1). Uri ne pre g na nc y tests will be 
a d mi nistere d peri o dicall y starti n g at 
W ee k [ADDRESS_1084085] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084086] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 7 8  Ori gi n al te xt wit h c h a n ges s h o w n  Ne w w or di n g  Re as o n/ J ustific ati o n f or 
c h a n ge  
I n a d diti o n t o t he sc he d ule d f oll o w -u p 
visits, s u bj ects will ret ur n f or la b orat or y 
visits t o pr o vi de bl o o d sa m ples f or M P A, P 
a n d E 2 at t he f oll o wi n g ti me p oi nts: Da ys 0, 
1, 2, 3, 5, 7, 1 0, 1 2, 1 4, 1 8, 2 1, a n d 2 8; 
W ee ks 6, 8, 1 0, 1 2, 1 3, 1 5, 1 7, 1 9, 2 1, 2 3, 
2 5, 2 6, 2 8, 3 0, a n d 3 2; a n d t he n e ver y 2 8 
da ys t hr o u g h W ee k 5 2. Bl o o d sa m ples f or P 
will b e c ollecte d at W ee ks 4 8, 4 9, 5 0, 5 1 
a n d 5 2. I n a d diti o n, starti n g o n Da y 2 8 
bl o o d sa m ples f or E 2 will be c ollecte d 
ever y ti me M P A or P is meas ure d.  at pre -
defi ne d ti me p oi nts (see T a ble 1).  I n a d diti o n t o t he sc he d ule d f oll o w -u p 
visits, s u bj ects will ret ur n f or la b orat or y 
visits t o pr o vi de bl o o d sa m ples f or M P A, 
P a n d E 2 at pre -defi ne d ti me p oi nts (see 
T a ble 1).  U p date.  C ollecti o n ti mes 
re m o ve d a n d re place wit h a 
refere nce t o T a ble 1.  
If t he s u bj ect has ne w or o n g oi n g I S R at 
W ee k 5 2, s he will be f oll o we d e ver y 3 
m o nt hs (at W ee ks 6 5 a n d 7 8) u ntil I S R 
res ol uti o n or M o nt h 1 8 ( W ee k 7 8), 
w hic he ver is earlier. If t he s u bj ect d oes n ot 
ha ve a n y I S Rs at W ee k [ADDRESS_1084087] has ne w or o n g oi n g I S Rs at 
W ee k 5 2, s he will be f oll o we d e ver y 3 
m o nt hs (at W ee ks 6 5 a n d 7 8) u ntil I S R 
res ol uti o n or M o nt h 1 8 ( W ee k 7 8), 
w hic he ver is earlier. If t he s u bj ect d oes 
n ot ha ve a n y I S Rs at W ee k [ADDRESS_1084088] 8 0 % of s u bj ects ha ve ha d a c ha nce t o 
c o m plete 7. [ADDRESS_1084089] 8 0 % 
of s u bj ects ha ve ha d a c ha nce t o c o m plete 
7. [ADDRESS_1084090] u d y ( T a ble 1).  S u bj ects will be i nter vie we d a b o ut as pects 
of a n d c ha n ges i n m o o d at scree ni n g a n d 
at pre -defi ne d ti me p oi nts  t hr o u g h o ut t he 
st u d y ( T a ble 1).  Clarificati o n. Ti me of 
assess me nts u p date d t o pre -
defi ne d ti me p oi nts  
Secti o n 5. 1. 9 .  I njecti o n Site Re a cti o ns (I S Rs)  
V V- [ADDRESS_1084091] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084092] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 7 9  Ori gi n al te xt wit h c h a n ges s h o w n  Ne w w or di n g  Re as o n/ J ustific ati o n f or 
c h a n ge  
I nj ecti o n site reacti o n (I S R) will be 
e val uate d  meas ure d as detaile d i n T a ble 1.  I nj ecti o n site reacti o n (I S R) will be 
e val uate d as detaile d i n T a ble 1.  Clarificati o n.  
F or t he p ur p ose of t his pr ot oc ol, i nj ecti o n 
site pai n will i ncl u de pai n ass ociate d wit h 
i nj ecti o n a n d a n y pai n or te n d er ness 
at/ar o u n d t he i nj ecti o n site.  F or t he p ur p ose 
of t his pr ot oc ol, i nj ecti o n site pai n will 
i ncl u de pai n ass ociate d wit h i nserti o n of t he 
nee dle, i nj ecti n g of t he dr u g, a n d a n y pai n 
or te n der ness at/ar o u n d t he i nj ecti o n site.  F or t he p ur p ose of t his pr ot oc ol, i nj ecti o n 
site pai n will i ncl u de pai n ass ociate d wit h 
i nj ecti o n a n d a n y pai n or te n d er ness 
at/ar o u n d t he i nj ecti o n site.  U p date. I nj ecti o n site 
descri pti o n u p date d.  
I nj ecti o n sites will be m o nit or e d f or t he 
pr o gress of o n g oi n g a n d/ or occ urre nce of 
ne w I S Rs. If t he s u bj ect has ne w or o n g oi n g 
I S R at W ee k 5 2, s he will be f oll o we d e ver y 
3 m o nt hs (at W ee ks 6 5 a n d 7 8) u ntil I S R 
res ol uti o n or W ee k 7 8, w hic he ver is earlier.    I nj ecti o n sites will be m o nit or e d f or t he 
pr o gress of o n g oi n g a n d/ or occ urre nce of 
ne w I S Rs. If t he s u bj ect has ne w or 
o n g oi n g I S R at W ee k 5 2, s he will b e 
f oll o we d e ver y 3 m o nt hs (at W ee ks 6 5 
a n d 7 8) u ntil I S R res ol uti o n or W ee k [ADDRESS_1084093]’s 
self -re p orts a n d vis ual e xa mi nati o n of t he 
site of i nj ecti o n b y bli n de d st u d y staff.  I S Rs will b e e val uate d at all st u d y  
ti me p oi nts liste d i n T a ble [ADDRESS_1084094]’s 
self -re p orts a n d vis ual e xa mi nati o n of t he 
site of i nj ecti o n b y bli n de d st u d y staff.  Clarificati o n. T a ble [ADDRESS_1084095] e d t o use 
n o n -lea di n g q uesti o n s (e g, “ D o y o u ha ve 
a n y ne w me dical iss ues si nce pre vi o us 
visit? ” ) h o w d oes t he i nj ecti o n site feel, d o 
y o u ha ve a n y ne w c o m plai nts a b o ut t he 
i nj ecti o n site si nce last visit)  f or I S R 
ascertai n me nt. I nj ecti o n site p ai n will be 
e val uate d b y self re p orts.  T he  st u d y staff will be i nstr uct e d t o use 
n o n -lea di n g q uesti o ns (e g, “ D o y o u ha ve 
a n y ne w me dical iss ues si nce pre vi o us 
visit? ”) f or I S R ascertai n me nt.  U p date. Q uesti o ns 
re gar di n g I S Rs re m o ve d. 
State me nt re gar ds self -
re p orts of I S Rs re m o ve d.  
If necessar y, a c o ns ultati o n wit h a n 
a p pr o priate cli nical e x pert ma y be 
sc he d ule d.  All cases of i nj ecti o n site 
disc ol orati o n ( h y p o pi g me ntati o n) will b e 
p h ot o gra p he d a n d c o ns ulte d b y a 
der mat ol o gist.  If necessar y, a c o ns ultati o n 
wit h a n a p pr o priate cli nical e x pert ma y be 
sc he d ule d.  All cases of i nj ecti o n site disc ol orati o n 
( h y p o pi g me ntati o n) will be p h ot o gra p he d. 
If necessar y, a c o ns ultati o n wit h a n 
a p pr o priate cli nical e x pert ma y be 
sc he d ule d.  U p date. Details descri bi n g 
I S R d oc u me ntati o n a n d 
e val uati o n u p date d.  
Secti o n 5. 2. 2.  Rec or di n g a n d Re p orti n g A d verse E ve nts  
F or t his st u d y, t he f oll o w u p peri o d is 
defi ne d as u p t o [ADDRESS_1084096] u d y u p date d.  
At t he sc he d ule d W ee k 1 ( Da y 7) a n d W ee k 
[ADDRESS_1084097] a b o ut a d verse e ve nts 
b y as ki n g a n o pe n -e n de d q uesti o n s uc h as, 
“ Ha ve y o u ha d a n y u n us ual s y m pt o ms or 
me dical pr o ble ms si nce t he last visit? If 
yes, please descri be.”  At t he sc he d ule d visits, t he i n vesti gat or 
will q uesti o n t he s u bj ect a b o ut a d verse 
e ve nts b y as ki n g a n o pe n -e n de d q uesti o n 
s uc h as, “ Ha ve y o u ha d a n y u n us ual 
s y m pt o ms or me dical pr o ble ms si nce t he 
last visit? If yes, please descri be.”  U p date. Da ys re m o ve d.  
Secti o n 5. 2. 5. 3. 1.   I n vesti g at or Res p o nsi bilit y  
V V- [ADDRESS_1084098] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084099] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 8 0  Ori gi n al te xt wit h c h a n ges s h o w n  Ne w w or di n g  Re as o n/ J ustific ati o n f or 
c h a n ge  
T he i n vesti gat or d oes n ot nee d t o acti vel y 
m o nit or s u bj ects f or a d verse e ve nts o nce 
t his st u d y has e n de d. Seri o us a d verse e ve nts 
occ urri n g t o a s u bj ect after t he treat me nt of 
t hat s u bj ect has e n de d will be re p orte d t o 
t he s p o ns or, wit hi n [ADDRESS_1084100]’s f oll o w -u p peri o d 
u p date d.  
Secti o n 5. 2. 9.  Pre g n a nc y  
D uri n g t he st u d y , a pre g na nc y test will be 
perf or me d if t he w o ma n is e x perie nci n g 
a n y s y m pt o ms or si g ns of pre g na nc y, or 
t hi n ks s he ma y be pre g na nt, a n d e ver y [ADDRESS_1084101] 
a b o ut t his met h o d, a n d w het her s he w o ul d 
use t his met h o d i n t he f ut ure a n d/ or 
rec o m me n d it t o a frie n d.  T he acce pta bilit y of t he differ e nt i nj ecti o n 
d oses a n d t reat me nt gr o u ps will be 
assesse d a n d rec or de d o n a p pr o priate 
st u d y C R Fs at W ee ks [ADDRESS_1084102] 
a b o ut t his met h o d, a n d w het her s he w o ul d 
use t his met h o d i n t he f ut ure a n d/ or 
rec o m me n d it t o a frie n d.  U p date. Ti mi n g of 
acce pta bilit y assess me nts 
u p date d. Q uesti o ns i ncl u de d 
i n t he assess me nt u p date d.  
Secti o n 9. 3. 4.  P h ar m ac o ki n etic A n al ysis Set  
F oll o w u p ti me will als o  be ce ns ore d after a 
s u bj ect i nitiates  use of a c o nc o mita nt 
me dicati o n k n o w n t o i m pact t he 
p har mac o ki netics of M P A.  T he a nal ysis set 
will e xcl u de M P A data c ollect e d d uri n g 
ti me peri o ds w he n s u bj ects us e d a 
c o nc o mita nt me dicati o n k n o w n t o i m pact 
t he p har mac o ki netics of M P A.  T h e a nal ysis set will e xcl u de M P A data 
c ollecte d d uri n g ti me peri o ds w he n 
s u bj ects use d a c o nc o mita nt me dicati o n 
k n o w n t o i m pact t he p har mac o ki netics of 
M P A.  U p date. Data e xcl u de d fr o m 
t he a nal ysis set u p date d.  
Secti o n 9. 5. 2.  De m o gr a p hic a n d B aseli ne C h ar a cteristics  
V V- [ADDRESS_1084103] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084104] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 8 1  Ori gi n al te xt wit h c h a n ges s h o w n  Ne w w or di n g  Re as o n/ J ustific ati o n f or 
c h a n ge  
S u bj ect d e m o gra p hic a n d baseli ne 
c haracteristics, i ncl u di n g me di cal hist or y, 
a n d pri or me dicati o ns  will be e xa mi ne d t o 
assess t he c o m para bilit y of t he treat me nts 
a n d will be s u m marize d usi n g descri pti ve 
statistics.  S u bj ect d e m o gra p hic a n d baseli ne 
c haracteristics, will be e xa mi ne d t o assess 
t he c o m para bilit y of t he treat me nts a n d 
will b e s u m marize d usi n g des cri pti ve 
statistics.  U p date. De m o gra p hics data 
c ollecte d u p date d.  
Secti o n 9. 6.  S afet y A n al ysis  
T he perce nta ge of w o me n e x p erie nci n g 
a me n orr hea or va gi nal blee di n g 
dist ur ba nces (irre g ular va gi nal blee di n g or 
s p otti n g) will li ke wise be s u m marize d 
descri pti vel y a n d c o m pare d bet wee n t he 
test a n d refere nce  treat me nt  gr o u ps. M o o d 
data will be s u m marize d i n ta bles at 
a p pr o xi matel y m o nt hl y Da y [ADDRESS_1084105] ur ba nces (irre g ular va gi nal blee di n g 
or s p otti n g) will li ke wise be s u m marize d 
descri pti vel y a n d c o m pare d bet wee n t he 
te st a n d refere nce  gr o u ps. M o o d data will 
be s u m marize d i n ta bles at Da y 0 a n d at 
f oll o w -u p visits.  U p date.  “ T est a n d 
refere nce” gr o u p a d de d. 
Ti mi n g of m o o d data 
s u m maries u p date d.  
Secti o n 9. 8.  Acce pt a bilit y A n al ysis  
T he res p o nses t o acce pta bilit y q uesti o ns at 
W ee ks [ADDRESS_1084106] 8 0 % of s u bj ects ha ve 
ha d a c ha nce t o c o m plete 7. [ADDRESS_1084107] 8 0 % of s u bj ects ha ve 
ha d a c ha nce t o c o m plete 7. [ADDRESS_1084108] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084109] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 8 2  Ori gi n al te xt wit h c h a n ges s h o w n  Ne w w or di n g  Re as o n/ J ustific ati o n f or 
c h a n ge  
 
 
 
As ociaci ó n D o mi nica na Pr o Bie nestar de la 
Fa milia, I nc. ( P R O F A MI LI A)  
  
 
 
 
 
I C O N  
 
 
 
 
  
W C C T  
 
  
 
 
As ociaci ó n D o mi nica na Pr o Bie nestar de 
la Fa milia, I nc. ( P R O F A MI LI A)  
  
 
 
 
 
I C O N  
 
 
 
 
ti gat or  
W C C T  
 
 U p date. A d diti o nal 
i n vesti gat ors i ncl u de d.  
  
F HI 3 6 0  
   
  
   
F HI 3 6 0  
   
  
 U p date. Title c ha n ge d.  
Ce ntral  I nstit uti o nal Re vie w B oar d s I nstit uti o nal Re vie w B oar ds  U p date. Ce ntral I R B 
re m o ve d.  
Mi dla n ds I R B  
8 2 0 7 Melr ose Dri ve, S uite 2 0 5  
Le ne xa, Ka nsas 6 6 2 1 4  
U nite d States of A merica  
 
Et hical C o m mittee of Pr ofa milia  
Clí nica A bre u, Calle B eller # 4 2 es q. A ve. 
I n de p e n de ncia  
Sa nt o D o mi n g o, D o mi nica n R e p u blic  
 
C O N A BI O S  
A ve. B olí var # 9 0 2, La J ulia  
Sa nt o D o mi n g o, D o mi nica n R e p u blic  
Pr otecti o n of H u ma n S u bj ects C o m mittee  
F HI 3 6 0  
 
 
 Mi dla n ds I R B  
8 2 0 7 Melr ose Dri ve, S uite 2 0 5  
Le ne xa, Ka nsas 6 6 2 1 4  
U nite d States of A merica  
 
Et hical C o m mittee of Pr ofa milia  
Clí nica A bre u, Calle B eller # 4 2  es q. A ve. 
I n de p e n de ncia  
Sa nt o D o mi n g o, D o mi nica n R e p u blic  
 
C O N A BI O S  
A ve. B olí var # [ADDRESS_1084110] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084111] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 8 3  A P P E N DI X  A.  S T U D Y R E S P O N SI BI LI TI E S   
S p o ns or’s A ut h orize d Re prese nt ati ve   
  
 
  
S p o ns or’s M e dic al E x pert    
 
N u ve ntra, I nc. ™  
 
 
 
S p o ns or’s S afet y Re prese nt ati ve   
 
T e va Bra n de d P har mace utical Pr o d ucts R & D, I nc.  
 
 
 
Site I n vesti g at ors   
 
As ociaci ó n D o mi nica na Pr o Bie nestar de la Fa milia, I nc. 
( P R O F A MI LI A)  
  
 
 
 
 
I C O N  
 
 
 
 
  
W C C T  
 
 
C o or di n ati n g I n vesti g at or    
F HI [ADDRESS_1084112] y M a n a ge me nt ( T S M) Ve n d or  Acta vis La b orat ories U T, I nc  
[ADDRESS_1084113] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084114] u d y T V 4 6 0 4 6 -W H -1 0 1 5 9  
 8 4  I nstit uti o n al Re vie w B o ar ds  W C G I R B  
1 0 1 9 3 9t h A ve., S E  
S uite 1 2 0  
P u yall u p, W A 9 8 3 7 4  
U nite d States of A merica  
 
Et hical C o m mittee of Pr ofa milia  
Clí nica A bre u, Calle B eller # 4 2 es q. A ve. I n de p e n de ncia  
Sa nt o D o mi n g o, D o mi nica n R e p u blic  
 
C O N A BI O S  
A ve. B olí var # [ADDRESS_1084115] u d y – Healt h y S u bjects  
Cli nical St u d y Pr ot oc ol wit h A me n d me nt [ADDRESS_1084116] r a n d o mizati o n n u m ber, sa m ple t y pe (e g, P K), st u d y 
peri o d (if a p plica ble), n o mi nal c ollecti o n ti me, sa m ple set ( A or B)  
Sa m ple 
pr ocessi n g 
(ser u m)  1.  C ollect sa m ples (a p pr o xi matel y 5 m L) i nt o V ac ut ai ner ® t u bes ( t u be 
re d t o p, 1 3 x 7 5 m m, silic o ne c o ate d i nteri or)  c o ntai ni n g n o 
a ntic oa g ula nt  
2.  I m me diat el y  after  t he  sa m ple  is  dra w n,  ge ntl y  i n vert  t he  t u be  [ADDRESS_1084117] 2 0 mi n utes ( n o 
m ore t ha n 4 0 mi n utes)  
3.  Ce ntrif u ge ~ 1 0 -1 5 mi n utes (at  r o o m  te m perat ure  at  2 5 0 0  t o  3 0 0 0  r p m  
[a p pr o xi matel y  6 5 0  t o  1 4 5 0  x g] ) t o ac hie ve a clear  ser u m  la yer  o ver  
t he  cl otte d  re d  cells  (t he  s pee d  a n d  ti me  ma y  be  v arie d  acc or di n g  t o  
t he  ma ke  a n d  m o del  of  ce ntrif u ge  use d)  
4.  Tra nsfer a p pr o xi matel y e q ual p orti o ns of se parate d ser u m (at least 
1 m L) i nt o 2 la bel e d, p ol y pr o p yle ne tra nsfer t u bes (sets  A a n d  B)  
St ora ge  Sa m ples will be st ore d at a te m pe rat ure of –2 0° C i n a n u pri g ht p ositi o n u ntil 
t he y are s hi p pe d t o t he bi oa nal yti cal la b orat or y. F or e ver y  M P A  bl o o d dr a w, 
batc h o ne ali q u ot (“ali q u ot 1”) f or e v e nt ual s hi p me nt t o P P D st ore, a n d o ne 
ali q u ot (“ali q u ot 2”) t o b e st ore d o n site d uri n g t h e st u d y  as b ac k u p i n c as e 
a d diti o nal testi n g is nee d e d.   
S hi p pi n g  T he bi oa nal ytical la b orat or y will be n otifie d pri or t o t he s hi p me nt of t he 
sa m ples. Pri mar y a n d bac k u p sa m ples are n ot t o be se nt i n t he sa me s hi p me nt.  
A n electr o nic file c o ntai ni n g sa m ple c ollec ti o n dat es will be e maile d t o t he 
bi oa nal ytical la b orat or y a n d t he s p o ns or’s bi oa nal ytical d e part me nt 
re pres e ntati ve f or eac h s hi p me nt.  
 
V V- 0 0 0 4 3 7 1 1 v 4. 0 